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CHARACTERIZATION OF THE IMMUNE RESPONSE

TO ANTI-MÜLLERIAN HORMONE
JUSTIN M. JOHNSON

ABSTRACT
Anti-Mullerian hormone (AMH) has been known since the mid-twentieth century
as the substance secreted by the testes of the male fetus that is responsible for directing

the proper development of the male reproductive organs from the primordial structures

that would otherwise become the uterus and fallopian tubes. However, despite its long-

known significance in male development, only recently has its importance in the adult
female become evident. AMH is now considered to be not only a clinical indicator of the

finite ovarian egg supply, but a vital regulator thereof throughout the reproductive life of
the female. Dysfunctions in AMH regulation may lead to infertility that underlies
conditions such as primary ovarian insufficiency (POI) and polycystic ovarian syndrome

(PCOS). Moreover, mounting clinical and experimental evidence suggests that many
such cases may be the result of autoimmunity to AMH. To test this hypothesis, an animal

model of AMH autoimmunity was developed by immunization of C57BL/6J female mice
with recombinant AMH protein. These mice developed a typical autoimmune profile
with a robust antigen-specific type-1/type-17 immune response with high frequencies of
CD4+ T cells that transiently infiltrated ovarian tissues as well as long-lasting high titers

of IgG1 and IgG2b in the serum. Most importantly, the mice exhibited a unique and
previously unreported phenotype in which their reproductive lifespan was extended.

Mice immunized with AMH in complete Freund's adjuvant (CFA) remained fertile at ten
months of age at a time when control mice immunized with CFA alone exhibited a

viii

natural decline in fertility due to reproductive senescence. AMH-immunized mice had
more litters, greater numbers of pups per litter, and conserved more active follicles than
controls at ten months. This effect correlated with a significant lengthening of the estrous
cycle, resulting in fewer cycles over time which did not reduce the probability of

conception or the health and viability of the offspring, but rather extended the fertile
lifespan of the mice. This novel model of experimental autoimmune oophoritis (EAO)
helps advance the knowledge of the physiologic role of AMH in the female, and may aid

in understanding and managing human health conditions such as menopause and
infertility.
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CHAPTER I

BACKGROUND AND INTRODUCTION

ANTI-MÜLLERIAN HORMONE

Introduction
Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting substance

(MIS) or Müllerian-inhibiting factor (MIF)1, is a homodimeric glycoprotein of the
transforming growth factor beta (TGFß) superfamily that is present in all vertebrates and

has important but disparate effects in both males and females. It was first described by
the French physician Alfred Jost (Jost, 1947) as the critical factor secreted by the testes
during male fetal development that caused regression of the Müllerian ducts—primordial

structures named for discoverer Johannes Peter Müller—which would otherwise develop
into the fallopian tubes, uterus, and upper vagina in the female (Roly, et al., 2018). In a
series of elegant experiments in rabbits using a pioneering intrauterine castration

technique (Jost, 1947; Jost, 1953), Jost showed that the effect of AMH, secreted by the

1 Other nomenclature variations exist, but AMH, MIS, and MIF appear most often in scientific literature.
AMH is the most universally recognized designation and was preferred by its discoverer (Josso, et al.,
1993); therefore it is the canonical term used in this document.

1

Sertoli cells of the testes, was independent of testosterone, which is secreted by the leydig
cells. Whereas testosterone could promote further development of the male urogenital

structures, it could not itself cause Mullerian duct regression. Jost reasoned that this
effect must be caused by some yet undiscovered hormone that he putatively termed
"Mullerian inhibitor" (Josso, 1991).

While it was widely known for many decades thereafter for its eponymous role in
male fetal development, only recently has AMH become appreciated for its function in

the sexually mature female as an important regulator of the ovarian cycle. Contemporary

research is primarily aimed at elucidating this regulatory mechanism, and at establishing

a clinical role for AMH—as a biomarker of fertility and ovarian pathology; as a possible
underlying cause of ovarian diseases that impair fertility, such as primary ovarian
insufficiency (POI) and polycystic ovary syndrome (PCOS); and as a potential treatment

for these and other diseases of the ovary. Mounting evidence suggests that autoimmunity
to ovarian proteins may play a role in many cases of infertility (Tuohy & Altuntas, 2007;
Sen, et al., 2014), and yet autoimmunity to AMH remains unexplored. Thus, the current
study characterizes the immunologic response to AMH and describes a novel phenotype

that may have important clinical implications.

AMH Expression and Activation

In humans, the AMH gene is located on chromosome 19 and is under the control
of a unique promoter (Josso, et al., 1993). It is expressed primarily in the ovaries and
testes as a primary transcript containing 5 exons that is spliced into an 1883 bp mRNA

(Cate, et al., 1986). The mature mRNA is subsequently translated to a 560 amino acid

2

59.2 kDa protein that contains two glycosylation sites, as well as four disulfide bonds that
stabilize the two chains of the mature homodimer (Josso, et al., 1993). Prior to secretion,

the signal peptide (residues 1-18) is cleaved. Once secreted, AMH must undergo a

proteolytic cleavage to become biologically active, in a manner similar to its close

relative TGFp. The 140 kDa mature homodimer is cleaved between R451 and S452 by
proteases in the gonadal environment resulting in a 110 kDa N-terminal proregion and a
25 kDa C-terminal active region (Pepinsky, et al., 1988). The C-terminal fragment by

itself is capable of biologic activity, whereas full-length AMH or the N-terminal
proregion alone are not (di Clemente, et al., 2010). Interestingly, it has been observed
that after cleavage, both regions remain non-covalently associated (Figure 1.1), and this
complex exhibits greater biologic activity than the C-terminal region alone (Wilson, et

al., 1993). AMH is highly conserved across mammalian species in terms of structure and

function; not surprisingly, the receptor-binding C-terminal domain is the most conserved
region, with human, bovine, mouse, and rat AMH-C-terminal domains sharing >90%

homology (Josso, et al., 1993).
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Full-length
Homodimer
N-terminal
Proregion
110 kDa

C-terminal
Active Region
25 kDa

Protease cleavage

Biologically
Active
Complex

Figure 1.1 AMH Cleavage and Biologically Active Complex. AMH is secreted as an
inactive 140 kDa disulfide-linked (solid black lines) homodimer that must be cleaved by
proteases in the ovarian microenvironment to become biologically active. The resulting
110 kDa proregion and 25 kDa active region homodimer fragments remain noncovalently associated (dotted black line) to induce maximal signaling through the
AMHR2 receptor. Diagram adapted from (Dewailly, et al., 2014).

AMH Signaling Pathway
As a member of the TGFP superfamily, AMH shares the canonical signaling

pathway that is common to the group: a ligand-binding type 2 receptor, an associated

type 1 receptor, and a cytoplasmic small mothers against decapentaplegic (SMAD)
cascade that activates transcription in the nucleus. AMH is known to have only one
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native receptor, anti-Mullerian hormone receptor type 2 (AMHR2)2 and three known type
1 activin receptor-like kinase (ALK) receptors: ALK2, ALK3, and ALK6. Unlike its

ligand AMH, which was first characterized in the early 1970s and subsequently isolated
and purified in 1984, the hunt for the AMH receptor proved to be a much more

confounding and difficult undertaking (Josso, et al., 1993). AMHR2 was finally
identified in 1994 as a novel transmembrane serine/threonine kinase receptor associated
with the Mullerian ducts (Baarends, et al., 1994). Subsequent work showed that in adult

women, AMHR2 is a 62.7 kDa transmembrane protein, with a 127 amino acid

extracellular domain, a 26 amino acid helical transmembrane domain, and a 403 amino
acid cytoplasmic domain (Uhlen, et al., 2015). In humans, the AMHR2 gene is located

on chromosome 12 and encodes an 11-exon transcript (Mishina, et al., 1997) with

multiple splice variants of unclear function (Faure, et al., 1996). Like AMH, AMHR2 is

highly conserved across mammalian species, especially in the ligand-binding region of
exon 2 (Mishina, et al., 1997). Upon binding of biologically-active AMH, AMHR2

forms a non-covalent complex with a transmembrane anti-Mullerian hormone receptor
type 1 (AMHR1; also AMHRI), causing the cytoplasmic domain of AMHR1 to become
phosphorylated. This in turn activates a signaling cascade through the SMAD 1/5/8

pathway (Figure 1.2). SMAD 1/5/8 then associates with SMAD 4, and the entire
complex translocates to the nucleus to activate the transcription of target genes (Josso, et

al., 2001).

2 Also abbreviated AMHRII or referred to as Mullerian inhibiting substance receptor type 2 (MISR2,
MISRII, or MISIIR). The abbreviation AMHR followed by arabic numerals is currently the preferred
format for AMH type 1 and type 2 receptors and are used as the standard throughout this document.
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Figure 1.2 AMH Receptor Signaling. AMH binds to the AMHR2 receptor, which then
complexes with AMHR1 triggering a SMAD 1/5/8 cascade. This SMAD 1/5/8 complex
joins with SMAD 4 and translocates to the nucleus to initiate expression of pro-apoptotic
genes. Reproduced with modification from (Goodman, 2009).

While the classical action of AMH—vis-à-vis the regression of the Mullerian

ducts in fetal male development—is well-defined, AMH appears to have additional roles
in the mature reproductive system. These include subtle and poorly understood
regulatory effects on spermatogenesis and the ovarian cycle (Durlinger, et al., 1999;

Fujisawa, et al., 2002). What is common among the seemingly disparate effects of AMH

is the ability to promote growth arrest and cell elimination. Not surprisingly, then, AMH

has been shown to regulate many pathways of cell cycle arrest and apoptosis (Seifer &
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Merhi, 2014; Rehman, et al., 2017; Anttonen, et al., 2011). As expected, AMHR2 is

expressed most abundantly in its canonical target reproductive tissues such as the
Mullerian ducts, testes, and ovaries. However, substantial expression of AMHR2 has

also been demonstrated in the adrenal gland, and minor expression has been shown in the

spleen, pancreas, and skeletal muscle (Uhlen, et al., 2015). Interestingly, AMHR2 in
non-reproductive tissues is expressed as a truncated isoform which lacks the extracellular
domain encoded by exons 1-3 of the mRNA transcript; and for reasons that remain
unclear, this extracellular domain is "retired" with age in the ovaries of post-menopausal

women and in comparably-aged mice, as its expression significantly diminishes
independently of the rest of the molecule (Mazumder, et al., 2017). It is also important to
note that AMH and AMHR2 expression patterns vary by species; for example, mRNA

encoding AMHR2 is broadly expressed in mouse and pig brain structures, but virtually
absent in the adult human brain (Uhlen, et al., 2015). Like its receptor, AMH expression

is predictably high in testes and ovaries, but it has been shown to be expressed in nonreproductive tissues as well, most notably in the brain. Conversely to AMHR2,

expression of AMH in the brain of humans is substantial, yet expression in the brains of
mice and pigs is virtually undetectable (Uhlen, et al., 2015). The actions and physiologic

relevance of AMH on organs outside of the reproductive system and remain speculative,
but the presence of the receptor in such diverse tissues suggests additional cryptic actions

of the AMH/AMHR2 pathway (McLennan & Pankhurst, 2015).
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AMH PHYSIOLOGY

AMH as a Hormone

Physiologically, AMH is a hormone with autocrine/paracrine effects; as such it is
not a true endocrine hormone and is occasionally referred to as a cytokine. It typically

exerts its effects locally in the gonadal microenvironment, acting on the secreting cell as
well as nearby cells. Paradoxically, it is readily detectable in the serum, reinforcing the

notion that it may have cryptic effects elsewhere in the body (McLennan & Pankhurst,
2015).

Sexual Dimorphism and Role in Males
AMH has sexually dimorphic expression patterns and disparate effects in males

and females. It is primarily expressed by the Sertoli cells of the testes and by the

granulosa cells of the ovaries; these cells have similar roles, as they both serve to secrete
hormones and regulatory factors to support and nurture developing sperm and ova,

respectively (Carre & Greenfield, 2016). However, the temporal expression pattern of
AMH is critically different between the sexes. As previously discussed, the canonical

role for AMH in the male fetus is to cause regression of the Mullerian ducts, which
would by default become female reproductive structures. Therefore, AMH measured in
serum is predictably highest in males during fetal development, remaining high until

puberty, and finally dropping to low but stable levels (Figure 1.3). In stark contrast, the

expression pattern in females is virtually the opposite, with no detectable serum AMH in
utero, gradually increasing amounts from birth through puberty, and reaching highest
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levels in early adulthood. In further contrast to males, after peaking in females, AMH
begins a steady lifelong decline to complete absence after menopause. These patterns

and the role(s) of AMH in both sexes after birth are still somewhat unclear. In mature
males, it is believed that AMH helps to regulate spermatogenesis (Rehman, et al., 2017).
In addition, there is growing evidence that AMH may exert masculinizing properties on
neurons, contributing both in the womb and in early childhood to the innate male

behavioral bias (Wang, et al., 2009).

Figure 1.3 Serum AMH Levels in Men and Women. AMH presents an extremely
sexually dimorphic and age-related expression pattern. In men (J), AMH is highest
before and after birth, then drops precipitously during puberty to low but stable levels. In
women ($), AMH is absent during fetal development but is detectable after birth, rising
significantly during puberty to a peak in the mid-twenties. After peaking, women exhibit
a steady lifelong decline to absence after menopause. Reproduced with modification
from (Kim, et al., 2014).
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Role in the Female

While the pioneering work of Alfred Jost in the middle of the twentieth century
paved the way to understanding the role of AMH during male fetal development, it was

not recognized that the hormone had any relevance in females until three decades later,
when it was unexpectedly discovered to be produced by the ovaries of hens (Hutson, et

al., 1981). Subsequent research showed that AMH expression in sexually mature females

was common to many mammalian species, including humans. Thus began the era of
intense interest in elucidating the function of AMH in the ovary, with early speculation
that it may play a regulatory role in the ovarian cycle (Josso, et al., 1993).

The Hypothalamic-Pituitary-Ovarian Axis and Ovarian Cycle

The ovarian cycle is a critical physiologic process that underlies female fertility,
ensuring the proper regulation and timing of ovulation. As endocrine glands, the ovaries

are under the master control of the pituitary, which is itself is directed by the

hypothalamus. The elegant coordination among these three elements is known as the
hypthothalamic-pituitary-ovarian axis (Figure 1.4). At the seat of control is the

hypothalamus, a small structure located below the cerebrum in front of the brain stem. It
is aptly classified as a “neuroendocrine” organ, as it forms a vital link between the

nervous and endocrine systems (Plant, 2015). It essentially functions as a master clock,
rhythmically secreting gonadotropin releasing hormone (GnRH), which acts on the

adjacent pituitary gland to stimulate secretion of follicle stimulating hormone (FSH) and
luteinizing hormone (LH). These latter two hormones are collectively responsible for
promoting follicle recruitment, maturation, and ovulation, and thus are the primary
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drivers of the ovarian cycle. Although the pituitary provides central control, the ovaries

themselves contribute to setting the tempo of the cycle by secreting critical hormones—
such as estrogen, progesterone, activin, and inhibin—that provide positive and negative

feedback to the pituitary. In addition, there are many important autocrine/paracrine
factors that act within the ovary itself to "fine tune" the ovarian cycle locally without any

direct feedback on the pituitary. Evidence has mounted over the past two decades that
AMH is one such regulatory factor (Durlinger, et al., 1999; Durlinger, et al., 2001;

Weenen, et al., 2004; Seifer & Merhi, 2014).

Hypothalamus

Stimulates
Inhibits
GnRH = gonadotropin-releasing hormone
FSH = follicle-stimulating hormone
LH = luteinizing hormone

Anterior
pituitary

Estrogen,
progesterone,
and inhibin
FSH + LH
surge

Estrogen

Primordial
follicle pool
Growing
follicle

Mature follicle

Ovulation

Corpus luteum

Figure 1.4 The Hypothalamic-Pituitary-Ovarian Axis. The hypothalamus acts
through GnRH as a master regulator of the pituitary gland. The pituitary imposes central
control over the ovarian cycle by secreting FSH and LH. The ovary provides feedback to
the pituitary through secretion of estrogen, progesterone and inhibin. AMH acts at a local
level within the ovary by limiting the number of follicles entering and exiting the
developing pool for each cycle. Reproduced with modification from (Gilbert & Barresi,
2016).
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The Menstrual Cycle

In humans and higher primates, the ovarian cycle forms the foundation of the

menstrual cycle, which encompasses all of the cyclical physiologic changes associated

with the reproductive system. The menstrual cycle ensures proper coordination between
the ovaries and uterus to maximize the potential for fertilization and successful gestation.
Females are born with a finite quantity of oocytes (the primordial ova or eggs) and this

supply cannot be replenished (Zuckerman, 1951)3. Therefore, careful regulation of
ovulation is critical in balancing a steady supply of ova for fertilization while maintaining
the ovarian reserve across a wide span of childbearing years. On average, a single ovum

is released every 28 days beginning at menarche, the onset of menstruation during
puberty, and lasting until menopause. This pattern results in a lifelong total of about 400
ovulations from the approximately 300,000 oocytes present at puberty (Seifer & Merhi,

2014; Walker & Herndon, 2008).
A single cycle begins with menses, the flow blood and endometrial tissue that is
expelled from the uterus in the absence of a pregnancy (Figure 1.5). This phase is
triggered by nadir levels of estrogen and progesterone, and typically lasts 5 days. It is

immediately followed by the follicular phase, which lasts 10 days on average and is

characterized by the development of a cohort of primary ovarian follicles as candidates
for ovulation (Clement & Monniaux, 2013). Each primary follicle originates from the
germinal epithelium of the ovary and initially consists of a sole oocyte surrounded by a

single layer of granulosa cells. The granulosa cells provide a nurturing environment for
the developing oocytes by supplying nutrients and growth factors (El-Hayek & Clarke,
3 This long-standing dogma of female fertility has been scientifically challenged (Johnson, et al., 2004), but
the concept of post-natal renewal of the ovarian supply by germline stem cells remains controversial (Kerr,
et al., 2012).
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2016). The growth and development of primary follicles during the follicular phase is
driven primarily by FSH secretion by the pituitary. During this time, follicles gradually
increase in size by adding multiple layers of granulosa cells and an external shell of

estrogen precursor-secreting theca cells (Magoffin, 2005) around the core to become

secondary follicles. This process continues until some of the follicles in the cohort
expand dramatically and develop fluid-filled cavities called antra. These antral follicles
continue to grow until one or more of them become very large mature or “Graafian”

follicles—the finalists for ovulation. These larger follicles begin to secrete high levels of
estrogen, which provides negative feedback to the pituitary, causing downregulation of

FSH production. While it is still unclear precisely how the dominant follicle is selected,
evidence suggests that one of the mature follicles becomes less dependent on FSH for

growth, and thus quickly outgrows its competitors (Hawkins & Matzuk, 2008). Those
follicles that are not selected for ovulation will be eliminated through atresia, an

apoptosis-driven process of involution and reabsorption. The sharp rise in estrogen
(which is inhibitory throughout the rest of the cycle, but is stimulatory in this context)

secreted by the dominant follicle prompts the pituitary to simultaneously release sharp
spikes of FSH and LH, triggering ovulation. During this process, the dominant follicle

docks with the ovarian epithelium and ruptures, releasing its ovum into the peritoneal
cavity.
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Figure 1.5 The Menstrual Cycle. The actions of the pituitary, ovaries, and uterus are
precisely coordinated in each cycle by a complex interplay of hormones and organ
physiology. (A) Pituitary gonadotropins FSH and LH exert master control over follicle
development and ovulation. (B) Follicles respond to pituitary signals to develop,
ovulate, and become corpora lutea. (C) Follicles provide feedback to the pituitary by
secreting the hormones estrogen and progesterone. (D) The uterus responds to hormonal
signals to prepare for pregnancy by a thickening of the endometrium; this lining is shed
each cycle in the absence of implantation of the blastocyst. One complete cycle lasts on
average 28 days. Reproduced from (Gilbert & Barresi, 2016).
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Ovulation is the watershed event in the cycle; it separates the follicular phase
from the subsequent luteal phase. Whereas the follicular phase is characterized by

follicular development culminating in release of a dominant ovum, the goal of the luteal

phase is to anticipate and prepare the uterus for pregnancy. It is characterized by a
dramatic rise in progesterone concurrent with high estrogen levels. These hormonal

signals cause the lining of the uterus to thicken and become highly vascular to support
implantation and growth of the fertilized ovum. The increase in estrogen also suppresses
production of FSH by the pituitary, ensuring that no additional follicles will mature
during this phase. Interestingly, the source of these luteal phase hormones is the

remnants of the dominant follicle in the ovary. In the absence of an ovum, the follicle

morphs into the corpus luteum, a distinctive yellowish-colored temporary endocrine
organ. It continues to secrete progesterone, as well as estrogen and inhibin, for
approximately two weeks. If during that time pregnancy occurs, then the menstrual cycle

is suspended; otherwise, menses will ensue and the cycle will begin again. It is important
to note that the human menstrual cycle is highly variable between individuals and also
among cycles in the same individual, especially near the beginning and end of the

reproductive lifespan (Mihm, et al., 2011). While 28 days is presented as a standard

human menstrual cycle, normal cycles may actually range from 24-35 days (Bakos, et al.,
1994).
Although control of the cycle is dominated by FSH, LH, estrogen, and

progesterone, other minor hormones dynamically influence the process. Activin and
inhibin are two hormones produced by the ovary that apply additional positive and
negative feedback, respectively, on the FSH production by the pituitary. Together, these
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hormones help maintain homeostatic levels of FSH. In addition, AMH exerts a local
influence on follicle maturation in a more subtle way. While AMH has no direct effect

on FSH secretion, it is believed that it opposes the action of FSH on follicles both at the

initial recruitment stage and at the maturation stage (Figure 1.6). Thus, AMH may act
analogously to the escapement wheel of a clock, a critical timing gear that is momentarily

inhibited on alternating sides with each swing of the pendulum. In a similar manner,
AMH likely limits both the entry and exit of follicles from the developing cohort in each

cycle. It has been demonstrated in an AMH null (-/-) mouse model that AMH is not
absolutely necessary in females for fertility. While males of this genotype have

predictably dysmorphic reproductive systems and are hence infertile, females are fertile
and able to deliver healthy litters. However, long-term studies in this model have shown
that these females exhaust their supply of oocytes early and become infertile significantly

sooner than wild type controls (Durlinger, et al., 1999). Thus, AMH may play a subtle
yet critical role as a gatekeeper of the precious finite oocyte supply over the fertile

lifespan of the host.

16

Figure 1.6 AMH and the Ovarian Cycle. AMH is produced by the granulosa cells of
small and large preantral and early antral follicles, and it exhibits inhibitory effects in two
distinct modes. It acts in an autocrine/paracrine fashion to limit entry of primordial
follicles into the developing pool (initial recruitment at a), and opposes the action of FSH
to limit recruitment of preovulatory follicles (cyclic recruitment at b). Reproduced from
(Broekmans, et al., 2008).

The Estrous Cycle

The menstrual cycle is unique to humans and higher primates; most mammals

undergo an analogous yet distinct process called the estrous cycle. While the two
processes share the same goal and are topologically and hormonally similar, there are
several important differences between the two. Firstly, in the estrous cycle, there is no

menses phase. Rather than being shed, the intrauterine lining is simply reabsorbed.
Although many mammals outwardly shed blood when they are sexually receptive or “in

heat,” this is not related to menstrual blood, and in fact is associated with ovulation in the
opposite part of the cycle. Secondly, because menses is effectively skipped, estrous
consists entirely of two phases in common with the menstrual cycle: follicular and luteal.

These are physiologically equivalent to their counterparts in the menstrual cycle, but are
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further divided into two stages each. Early follicular phase is termed proestrus, and the

latter portion including ovulation is estrus (distinct from estrous). Post-ovulation begins
the luteal phase, which is subdivided into metestrus and diestrus. Each of these four
stages is readily identified by vaginal smear; the relative abundance and shape of shed

epithelial cells and leukocytes is a distinguishing trait (Cora, et al., 2015). Lastly,

females with estrous cycles are sexually receptive only during the estrus phase, when

fertility is greatest. This behavior has an obvious reproductive advantage, and is believed
to hold true of most primates with menstrual cycles—with the notable exception of

human females, who are potentially receptive at any point in their cycles (Motta-Mena &
Puts, 2017).

The mouse (Mus musculus) exhibits a typical estrous cycle, lasting on average 4-5

days, spending approximately one day in each of the four stages. In contrast to humans
who rarely birth more than one offspring at a time, mice typically give birth to litters of
between 1-10 pups depending on the strain, and the number of eggs released at ovulation

is believed to be roughly equivalent to litter size (The Staff of The Jackson Laboratory,
1966).

AMH in Reproductive Senescence and Menopause

As previously mentioned, AMH has sexually dimorphic expression patterns,
extending into advanced age. In adult males, AMH drops to very low but sustained

levels; in reproductive-age females, it peaks early and declines steadily until menopause,
when it permanently drops to undetectable levels. Unlike most other reproductive

hormones, AMH is known to be expressed at relatively steady levels throughout the
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entire ovarian cycle (La Marca, et al., 2010). However, since it is secreted by granulosa
cells, its expression is directly proportional to the ovarian reserve, i.e., the total number of
remaining follicles in both ovaries. As this number steadily declines, so does the level of
AMH (Figure 1.7). Because of this correlation, serum AMH levels have become a

widely accepted clinical marker of ovarian reserve (Kevenaar, et al., 2006; Broer, et al.,

2014). Evidence suggests that it may even be useful in predicting the age at menopause
(Tehrani, et al., 2011; Kruszynska & Slowinska-Srzednicka, 2017).

Figure 1.7 Lifetime Decline in Serum AMH Levels in Women. Serum AMH levels
were clinically assessed in women aged 24-50 in a multi-center retrospective study with
data from more than 17,000 patients. The mean values (black circles) dropped steadily
with age across the entire range of the study. The average AMH serum concentration
declined 0.2 ng/mL/year from ages 24-35, then tapered to 0.1 ng/mL/year from ages 36
50. At 50, an age typically at or near menopause, the mean dropped to zero. Error bars
represent ±SD. Replotted from (Seifer, et al., 2011).
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Menopause represents the time in a woman's life after her final menstrual period,
and it is clinically defined retrospectively as the cessation of spontaneous menstruation
for one year (Takahashi & Johnson, 2015). Among industrialized nations, the median

age of menopause ranges from 50-52 years, with early symptoms typically beginning

with the transitional phase of perimenopause around age 47; however, ethnicity and
lifestyle factors may affect age of onset (Gold, 2011). Menopause is a natural process

associated with aging and senescence, and signifies the end of a woman’s reproductive

lifespan. It is believed that the underlying cause is the complete exhaustion of the
ovarian reserve, resulting in cessation of the ovarian cycle. This condition in turn leads

to a precipitous drop in estrogen, progesterone, and inhibin production. Without the

negative feedback imposed by these hormones on the pituitary, FSH levels maintain a
steady high state. The depletion of the ovarian reserve causes AMH to permanently drop

to undetectable levels (Bertone-Johnson, et al., 2018). These major hormonal shifts are

hallmarks of menopause and underlie substantial physiological and psychological
changes. While menopause is not a disease state, it may bring about serious health
issues, such as pronounced bone density loss (osteoporosis) and increased risk of

cardiovascular disease. Other symptoms can negatively affect quality of life, such as hot

flashes, night sweats, vaginal dryness, migraines, decreased libido, and depression

(Skaznik-Wikiel, et al., 2015). While many women embrace this life change that brings
liberation from menstruation and pregnancy, others may seek hormone therapy to
alleviate unpleasant side effects (Thacker, 2009). Many others lament the inability to

conceive, particularly when menopause is premature due to natural variation or
pathological factors. In this context, AMH may be useful not only as a gauge of ovarian
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reserve, but also as a predictor of in vitro fertilization (IVF) success for women who
struggle to conceive as they approach the age of menopause (La Marca, et al., 2010).

AMH DYSFUNCTION AND DISEASE

AMH Dysfunction in Development

Early clues to the existence and function of AMH came from observations in
cases of its dysfunction. When AMH signaling is weak or absent in the male fetus, the
Mullerian ducts fail to regress, resulting in a condition known as persistent Mullerian
duct syndrome (PMDS). Males with PMDS typically exhibit a normal male phenotype

and external genitalia. However, one or both testes may be undescended
(cryptorchidism), often accompanied by inguinal hernia. Female reproductive structures,
such as the uterus and fallopian tubes, are present and often require surgical removal.

Surprisingly, many males with PMDS are fertile, or can become so with medical
intervention. PMDS may be caused by defects in either AMH or AMHR2 expression

(Josso, et al., 2005), which suggests that no alternative ligand, receptor, or pathway exists
that can compensate these deficiencies.

Conversely, problems can also arise in female fetal development when AMH is

expressed inappropriately; this disorder causes regression of the Mullerian ducts typical
of the male phenotype, causing infertility. A similar condition known as freemartinism in

cows may be the earliest recorded observation of AMH dysfunction. Freemartin calves
are females from a male/female pair of twins that share a placenta; AMH secretion from

the male passes to the female, causing improper Mullerian duct regression and infertility
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(Munsterberg & Lovell-Badge, 1991). AMH null (-/-) male mice serve as an excellent
model for PMDS. Conversely, a transgenic mouse model has been developed in which
AMH is overexpressed shortly after birth. This type of postnatal overexpression of AMH

results in impaired fertility in females (McLennan, et al., 2017). Taken together, these
naturally-occurring defects and their respective mouse models have provided invaluable
understanding of the function of the AMH/AMHR2 signaling pathway.

Primary Ovarian Insufficiency (POI)
Primary ovarian insufficiency (POI), also known as premature ovarian failure

(POF)4, is an abnormal condition in which the ovaries cease to function before the age of

40. POI results in symptoms characteristic of menopause—amenorrhea (failure to
menstruate), anovulation (failure to ovulate), early depletion of the ovarian reserve, and
hormonal changes including decreased estrogen and elevated FSH (Kovanci & Schutt,

2015). As in menopause, serum AMH levels (Figure 1.8) are generally low or
undetectable (Meduri, et al., 2007). However, it is important to note that POI is a
pathological condition and not simply premature menopause (Kalantaridou & Nelson,

2000). POI is estimated to affect 1-3% of women under 40 (Kovanci & Schutt, 2015).
Known causes include genetic disorders, infections, environmental toxins, chemotherapy,

radiation, surgery, and autoimmunity (Ebrahimi & Asbagh, 2001). In most cases,
however, the specific etiology cannot be determined. It is presently unclear whether the
drop in AMH production is simply a useful clinical marker, or whether AMH

4 Primary ovarian insufficiency (POI) was proposed to replace premature ovarian failure (POF) as it better
describes the condition in scientific terms and is less stigmatizing to patients (Welt, 2008); it is therefore
the preferred term in this document.
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dysregulation may in fact play a mechanistic role in the pathology of the disorder
(Meduri, et al., 2007).

Control

POOS

POI

Figure 1.8 Serum AMH Levels in PCOS and POI. Serum levels of AMH as measured
by ELISA are dramatically elevated over normal controls in patients with PCOS and
extremely low or undetectable in patients with POI (P < 0.05). Reproduced with
modification from (La Marca, et al., 2006).

Current treatment options for POI are limited, and often egg donation is the only
solution. However, in some patients, small numbers of residual dormant follicles remain,

and recent studies have shown that in vitro activation of these primordial follicles is
possible and may lead to novel infertility treatments (Kawamura, et al., 2016).
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Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is a disorder in which an abnormal excess of
antral follicles, also termed "cysts", accumulate in the ovaries. It is the most common
female reproductive disorder, affecting up to 10% of all women (Broekmans & Fauser,

2006). In addition to the excess of ovarian cysts, distinguishing symptoms of PCOS
include irregularity or absence of menses, as well as aberrant elevation of male sex

hormones which can cause hirsutism, acne, and hair loss. PCOS is often accompanied by
metabolic abnormalities such as insulin resistance, metabolic syndrome, and obesity

(Moran, et al., 2015).
In stark contrast to POI, serum AMH levels in PCOS are abnormally high (Figure

1.8). Typically, the concentration is two to three times greater than normal, which is

proportional to the increased numbers of follicles present (Weenen, et al., 2004). Serum
AMH levels are therefore useful in the clinical diagnosis of PCOS (Sathyapalan, et al.,

2017). More importantly, AMH dysregulation may be directly involved in the pathology
of the disease (Dewailly, et al., 2014). Evidence suggests that initially, inadequate AMH

secretion by primary follicles is responsible for over-recruitment of follicles into the
developing pool, and subsequent overproduction of AMH by mature follicles may block
ovulation by nullifying the effects of FSH (Qi, et al., 2016). This suggests a possible
biphasic mechanism by which a surplus of follicles becomes indefinitely "stuck" in the

ovaries, and also implies a potential route for treatment.
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AMH in Endometriosis

Endometriosis is a common gynecological disease in which endometrial tissue grows
ectopically outside the uterus. This condition can cause severe pelvic and back pain,
abnormal menstruation, and fertility problems. Although it affects approximately 5% of
women, the etiology is still unknown (Vercellini, et al., 2014). However, it has recently

been shown that endometrial tissue normally expresses AMH and AMHR2, and that this

circuit may act in a paracrine fashion to regulate endometrial growth (Wang, et al., 2009).
It has been suggested that a defect in signaling may underlie the disease pathogenesis,
and that exogenous AMH therapy can potentially serve as a treatment by enhancing cell

cycle arrest and apoptosis of the aberrant tissue (Signorile, et al., 2014).

AMH and Cancer
In addition to its established diagnostic role in POI and PCOS, AMH may also

prove to be a valuable clinical marker of ovarian cancer. While ovarian tumors of
granulosa cell origin are relatively uncommon, accounting for only 3% to 5% of all
ovarian neoplasms, serum AMH levels have been shown to be greatly elevated in patients

with progressive granulosa cell tumors (GCTs), which then return to normal range upon
remission (Rey, et al., 1996). It has also been demonstrated that serum AMH levels

directly correlate with aggregate tumor mass (Chang, et al., 2009). These associations
make AMH not only useful in detection, but also for evaluating the efficacy of ongoing

treatment.
In addition to its clinical diagnostic value, AMH has shown promise per se as a

cancer treatment. Since the biologic function of AMH is to induce cell growth arrest and
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apoptosis, it may be intrinsically therapeutic for any tumor expressing AMHR2. This

receptor has been detected in GCTs, epithelial ovarian carcinomas (EOCs), breast cancer,
prostate cancer, and even ocular melanoma (Kim, et al., 2014). Conversely, AMH

expression has been shown to be significantly decreased or absent in GCTs larger than 10
cm (Anttonen, et al., 2005). The putative downregulation of AMH suggests a mechanism
by which tumors may escape growth regulation, and also presents a strategy to overcome

it. Treatment of human GCT lines in vitro with recombinant AMH has demonstrated its
ability to eliminate tumor cells by apoptosis (Anttonen, et al., 2011). Furthermore, a
potential clinical application of AMH as a cancer therapy has been successfully tested in

a patient-derived xenograft (PDX) model, in which the growth of chemoresistant EOCs
were effectively inhibited (Pepin, et al., 2015).

As an alternative approach to exploit the AMH signaling pathway to inhibit
tumors, the AMH receptor may be targeted immunologically. Successful inhibition of
EOCs in mice has been achieved by active immunization with the cytoplasmic domain of

AMHR2 (Sakalar, et al., 2015) as well as with passive transfer of antibodies to the
extracellular domain of AMHR2 (Mazumder, et al., 2017). Taken together, these
strategies represent a new horizon in treatment of gynecologic and other malignancies.

AMH AUTOIMMUNITY

General Features of Autoimmunity

Autoimmunity is defined as an inappropriate sustained immune response against
the host. The immune system has long been described as having the broad capability of
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distinguishing "self" from "non-self," with its primary function focused on detection and
eradication of non-self elements such as pathogens and foreign materials that pose
imminent threats to survival and well-being (Burnet, et al., 1941). However, more recent

views indicate that the primary role of the immune system is to recognize “danger”
signaled by pathogens through pattern recognition molecules (Matzinger, 1994). In any

event, it has long been recognized that the immense power of the immune system could

potentially be misdirected against the host itself and cause great harm, and that the
immune system must naturally exercise restraint against such an attack. This concept

was named "horror autotoxicus" by the pioneering immunologist Paul Ehrlich, and it
formed the foundation of the modern view of immunologic tolerance (Punt, et al., 2019).
While tolerance is actively established and maintained at multiple levels in

healthy individuals, it can often fail. An unrestrained autoimmune attack may result in
acute or chronic conditions with serious damage to tissues and harmful physiologic
consequences. For example, in multiple sclerosis (MS), a T cell-mediated autoimmune

attack against the myelin sheath of motor neuron axons causes limb weakness and
paralysis (Constantinescu, et al., 2011). A humoral response can also mediate

autoimmune disease, as in the case of myasthenia gravis (MG), a disorder in which
antibodies recognize acetylcholine receptors at neuromuscular junctions thereby blocking

normal transmission of signals, causing progressive muscle weakening, and eventually

destroying the junctions themselves (Gilhus, 2016). However, autoimmunity is rarely
mediated by a single arm of the immune system. The complex interplay among antigen

presenting cells, T cells, and B cells creates a web of co-dependence in which no

component acts alone. For example, although MS is primarily T cell-mediated,
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autoantibodies have been shown to play a significant role in the pathogenesis of the
disease (Kapadia & Dmytriw, 2020).
In all autoimmune diseases, tolerance has failed at some level; when tolerance

fails at a grand level, rampant autoimmunity often results. In the syndrome known as

IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked), a major
component in the active maintenance of immunologic tolerance—regulatory T cells

(Tregs)—are severely impaired. This defect can lead to wide ranging consequences,

including skin and intestinal disorders, anemia, diabetes, and thyroiditis (Husebye, et al.,
2018).
To date, over 80 autoimmune diseases have been identified, affecting as much as

8% of the human population (Punt, et al., 2019). Although the etiologies of many of
these conditions have been elucidated, the specific causes and underlying mechanisms for

the majority are still poorly understood. Furthermore, there are many other diseases not
traditionally considered autoimmune in which autoimmunity is now understood to play a

role, such as in atherosclerosis (Schoenfeld, et al., 2005). Still more diseases of unknown

etiology exist in which autoimmunity may be the cause in at least a subset of patients,
such as in hearing loss (Solares, et al., 2003), infertility (Tuohy & Altuntas, 2007), and

heart failure (Jane-wit, et al., 2007). These latter cases are of particular interest to
researchers and clinicians as they represent potentially unrecognized pathologies and

present pathways for novel therapeutic interventions.
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Organ-Specific Autoimmunity

Autoimmunity may target a single organ, an entire organ system, or multiple
systems throughout the host. In diabetes mellitus type 1 (T1DM), the attack is focused
entirely on the pancreas, and it is directed specifically at the insulin producing beta cells

within the organ (Katsarou, et al., 2017). Multiple sclerosis extensively afflicts the
central nervous system (CNS), causing lesions in the optic nerves, spinal cord, and brain

(Constantinescu, et al., 2011). Systemic lupus erythematosis (SLE) causes widespread
damage across diverse organs such as the skin, lungs, kidneys, and joints (Rekvig & Van
der Vlag, 2014). The range of sites affected can often be attributed to a single target that

is broadly distributed, such as myelin in MS, or DNA in SLE. In general, organ-specific
autoimmunity lends itself well to scientific research, as the causes and effects are focused

and animal models are readily available or relatively straightforward to develop.

Animal Models of Autoimmunity
The most beneficial tool in autoimmunity research is the animal model of human
disease. With an animal as a surrogate, a researcher can explore pathogenic mechanisms

and test novel treatments in a way that would not be possible in human patients. While

no research animal is a perfect reflection of the human anatomy and physiology, the
results of animal studies can be extrapolated to significant extent in the human.

The earliest and best-studied model of autoimmune disease is experimental

autoimmune encephalomyelitis (EAE), which closely mimics human MS. It was first
developed in the 1930s by Rivers and Schwentker, who elicited ataxia and lesions of the
CNS myelin in rhesus monkeys after repeated intramuscular injections of rabbit brain
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extracts (Rivers & Schwentker, 1935). This method was further refined over time by

substituting crude brain extracts with specific proteins or peptides derived from CNS
myelin, such as proteolipid protein (PLP), myelin basic protein (MBP), or myelin

oligodendrocyte glycoprotein (MOG). The immunogenicity of these antigens is
increased by combining them in an emulsion with complete Freund's adjuvant (CFA), a
mixture of paraffin oil and dead Mycobacterium tuberculosis extract (Constantinescu, et

al., 2011). This method is sufficient to break intrinsic immunologic tolerance and cause a

chronic and debilitating autoimmune disease in mice. It also serves as a paradigm for

creating new mouse models of organ-specific autoimmune disease, whereby an
investigator identifies a suitable organ-specific protein, generates the recombinant protein
or synthetic peptide of an appropriate region of the protein, and immunizes the animal

and evaluates the disease phenotype. Since the development of the EAE model nearly a

century ago, this paradigm has been used to develop scores of models for autoimmune
diseases of nearly every type. However, many further human disorders—both known and

undiscovered—still await the development of appropriate animal models.

Autoimmunity in Ovarian Dysfunction
Ovarian autoimmunity represents a potentially under-recognized pathology (Sen,

et al., 2014). It is estimated that infertility (clinically defined as failure to conceive after
12 consecutive months of regular intercourse) affects approximately 11% of women of

childbearing age (Luborsky, et al., 2011). Female infertility may result from anovulation,
endocrine irregularities, mechanical causes, or idiopathic (unexplained) reasons (Carp, et

al., 2012). Often overlooked is the possibility that autoimmunity may underlie infertility
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in any of these four broad categories. This fact may be especially relevant in idiopathic
cases, which comprise as many as 20% of all female infertility diagnoses (Deroux, et al.,

2017). More intriguingly, autoimmunity may also represent the root cause in at least a
cohort of patients with classically characterized disease. Of the approximately 8% of the

human population living with autoimmune disease, for reasons that remain unresolved,
women are more likely than men to be afflicted by a factor of approximately 3:1 (Smith

& Germolec, 1999). This disproportionality gives additional impetus to investigate the

role of autoimmunity in female infertility.
The prospect of autoimmunity as a cause of human infertility was first explored in
the early 1960s. It was recognized that patients with known autoimmune endocrine
diseases involving the thyroid or adrenal glands, or autoimmune polyendocrine

syndromes (APS), often presented with POI (Moncayo & Moncayo, 1992), and that
general immunosuppression in such cases could often restore ovarian function (Coulam,

et al., 1981). Endocrine autoimmunity, particularly of the thyroid, has also been strongly
associated with the development of PCOS (Novais, et al., 2015; Mobeen, et al., 2016).

As a hormone-responsive organ, it is obvious how dysfunction of the ovary can result
secondarily to systemic hormone irregularities caused by organ-specific autoimmunity in
another endocrine gland. However, it has also been shown that infertility is often a

component in many diverse autoimmune diseases, such as myasthenia gravis, SLE,

rheumatoid arthritis, MS, Sjögren syndrome, T1DM, and vitiligo (Moncayo & Moncayo,
1992; Carp, et al., 2012; Silva, et al., 2014; Sen, et al., 2014). In all of these examples,
the ovary is indirectly or non-specifically disrupted by factors such as hormonal changes,
the failure of other organs, overall poor health, or antibodies to ubiquitous targets, such as
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DNA and phospholipids. In the case of thyroid autoimmunity, it has been demonstrated
that autoreactive antibodies specific for thyroid hormones that are present in the serum

and ovarian follicular fluid are associated with reduced fertility (Monteleone, et al.,

2011). However, the ovary itself may be the primary target of an organ-specific
inflammatory autoimmune attack; this condition is known as autoimmune oophoritis
(AO), and it typically results in POI. It is currently estimated that AO accounts for 5% of

all POI cases (La Marca, et al., 2010).
Clinical AO is characterized by autoantibodies to the steroid-producing cells of

the ovary and/or T cell infiltration of ovarian tissues. The cells targeted may include the
follicular theca cells, granulosa cells, or the oocyte itself, as well as the corpus luteum.

Antibodies to specific antigens that have been identified include steroidogenic enzymes,

FSH and LH receptors, and the zona pellucida (Silva, et al., 2014). Autoimmune
oophoritis may be diagnosed by the presence of ovarian autoantibodies in serum and/or
mononuclear inflammatory cell infiltration detected by biopsy (Gao, et al., 2017). These

observations have compelled the development of animal models of human infertility as
well as having suggested possible ovarian-specific self-proteins as immune targets for

creating them.

Animal Models of Ovarian Autoimmunity
The ovary presents an appealing target for autoimmunity research. Unlike the
male testis, which is considered an "immunologically privileged" organ that restricts

entry of cells of the immune system, the ovary is readily accessible and well-vascularized
(Warren, et al., 2014). As in other historical autoimmunity models, the earliest attempts
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at developing ovarian autoimmunity involved immunizing animals with crude
homogenate derived from the target organ. This strategy first proved successful in a
pioneering study in which rats were immunized with crude bovine ovarian homogenate in

a CFA emulsion (Jankovic, et al., 1973). The rats developed oophoritis with lymphocytic
infiltration 14 days after immunization, as well as ovarian-specific serum antibodies at 28

days. Thus, having the hallmarks of AO, this was the first useful experimental model for
studying human AO, and provided the earliest example of experimental autoimmune

oophoritis (EAO).
An early alternative approach to inducing EAO did not involve immunization

with an antigen, but rather initiated the disease by neonatal thymectomy (NTx). It had

been well-established that removal of the thymus in mice in a critical window 2-4 days
after birth could induce multi-organ autoimmunity, such as thyroiditis, gastritis, and
oophoritis (Kojima & Prehn, 1981), in a manner similar to human APS. Taguchi &
colleagues further characterized this model by establishing that 3-day-old thymectomized

mice produce oocyte autoantibodies (Taguchi, et al., 1980) and further demonstrated that
this oophoritis could be passively transferred into normal syngeneic recipients using

enriched T cells alone (Taguchi & Nishizuka, 1980), thus reinforcing the dual roles of
cellular and humoral immunity in the pathogenesis of AO. Additional studies in the
model revealed an acute lymphocytic infiltration, rapid loss of oocytes, ovarian atrophy,

autoantibodies to several ovarian components including ooplasm, zona pellucida (sperm
binding region), and steroid producing cells (Miyake, et al., 1988), leading the authors to

propose it as a model for human POI. Notably, in addition to these similarities to the
clinical condition, the mice also exhibited irregular estrous cycles analogous to the
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irregular menstrual periods (oligomenorrhea) that are often a symptom of human POI
(Shestakova, et al., 2016).

Studies into the mechanisms of NTx-induced autoimmunity have revealed that the
primary cause is the depletion of Treg cells that would otherwise restrain any pathogenic

autoreactive T cells that had already escaped thymic deletion (Asano, et al., 1996).
Similarly, a thymic defect in which the autoimmune regulator (AIRE) gene is deleted has

been shown in a mouse model to cause ovarian T cell infiltration, early follicle depletion,
and infertility (Jasti, et al., 2012). AIRE is known to activate organ-specific proteins not

natively expressed in the thymus, and its function is critical to eliminating tissue-specific
autoreactive T cells from the repertoire through a negative selection process (Passos, et
al., 2018). AIRE-deficient mice also exhibit a range of polyglandular autoimmunity that

mirrors human APS. Not surprisingly, defects in AIRE are also responsible for causing
APS type-1, also known as autoimmune polyendocrinopathy-candidiasis-ectodermal

dystrophy or APECED (Aaltonen, et al., 1997).
More recently, as many of the specific targets of ovarian autoimmunity have been

speculated or identified, the original autoantigen-induced model of EAO has been

revisited and further refined by replacing crude ovarian homogenate with defined ovarian
proteins and peptides. For example, after the discovery of autoantibodies to the oocyte

zona pellucida in human and pig sera (Shivers & Dunbar, 1977), another group showed
that immunization of mice with synthetic peptides derived from the sequence of zona
pellucida sperm-binding protein 3 (ZP3) produced classic EAO with substantial follicular

T cell infiltration and high ZP3-specific antibody titers in the serum (Rhim, et al., 1992).

As in the NTx model of autoimmunity, adoptive transfer of activated T cells alone from
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mice immunized with ZP3 peptide can produce EAO in naive recipients (Hoek, et al.,

1997).
Building upon the ovarian self-antigen induction strategy, Altuntas and colleagues

developed a novel model of EAO with an intriguing biphasic phenotype (Altuntas, et al.,
2006). Immunization with a peptide derived from mouse inhibin-a yielded classic
symptoms of POI: ovarian T cell infiltrates, high titers of circulating ovarian-specific
antibodies, increased levels of serum FSH, and irregular estrous cycles with a prolonged

luteal phase. Surprisingly, however, these mice exhibited an early enhancement of

ovulation with gross ovarian hypertrophy and numbers of active follicles significantly
higher than controls at four weeks after immunization. This finding was supported by an

enhanced fertility as measured by an increased production of pups when mated with
normal males 7-9 weeks after immunization with peptide. In stark contrast, when
evaluated at 43-45 weeks, inhibin-a immunized mice showed a sharp decline in fertility

as evidenced by abnormally low litter sizes and ovarian atrophy. Unlike previous

models, EAO could not be passively transferred using purified antigen-specific T cells,
but rather B cells or serum alone from immunized mice were capable of producing the

phenotype in naive recipients. Thus, it was speculated and subsequently demonstrated
that the observed pathology in inhibin-a induced ovarian autoimmunity is mediated by

autoantibody neutralization of the biologic activity of inhibin-a. With the negative
feedback on pituitary production of FSH alleviated, increased production of FSH leads to

superovulation and transient increased fertility; the eventual outcome of this elevated
output is a premature depletion of the ovarian reserve, resulting in the classic POI
observed at the later time point. This curious biphasic phenotype led the authors to
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speculate that perhaps superovulation might be a clinically silent and previously
unknown component of the early phase of human POI where women are unknowingly

highly fertile.

As underscored by the aforementioned study, there is much still unknown about
ovarian autoimmunity. Given the broad spectrum of human ovarian disease and the

relatively few animal models available for scientific study, the development of additional
models is necessary. EAO has only been achieved using a handful of defined antigens,

and scores of ovary-specific proteins are still untested using this paradigm. Among these

proteins, AMH stands out not only because if its potential as an ovarian-specific self
protein, but also because its natural function and its relationship to ovarian disease is still
poorly understood. For these reasons, the consequences of autoimmunity against AMH

was chosen as the focus of the studies presented here.
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CHAPTER II

MATERIALS AND METHODS

Cloning of the mAMH Gene
Fresh ovaries were removed from normal healthy 8-week-old euthanized female
SWXJ mice (The Jackson Laboratory, Bar Harbor, ME). The tissues were dissected and
the RNA was extracted using an RNeasy kit (Qiagen, Valencia, CA). Complementary

DNA (cDNA) was generated from total RNA using a RETROscript® first strand

synthesis kit (Ambion, Austin, TX) with random decamers. The mAMH gene was
amplified by reverse transcription polymerase chain reaction (RT-PCR) using Platinum
pfx DNA polymerase (Invitrogen, Carlsbad, CA) and custom gene-specific primers

(Table 2.1) for 25 cycles with an annealing temperature of 65oC. The PCR product was

electrophoresed and a 1668 bp fragment was excised and cloned into a TOPO Zero Blunt

vector (Invitrogen) and transformed into DH5a chemically competent E. coli
(Invitrogen). TOPO clones were miniprepped with a QIAprep spin miniprep kit (Qiagen)
and analyzed by restriction digests with EcoRI to show presence of the insert and with
SmaI (Roche Diagnostics, Indianapolis, IN) to show orientation of the insert. A
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candidate clone was selected and sequenced to confirm the identity of the gene (NCBI

reference sequence NM_007445.3) and no mutations were observed.

Target

mAMH

Primer

Sequence (5’- 3’)

Forward

ATGCAGGGGCCACACCTCTCTCCACT

Reverse

TCACCGGCAGCCGCACTCGG

Amplicon
Length (bp)
1668

Table 2.1 Primers for Cloning the mAMH Gene. RNA was extracted from fresh
mouse ovarian tissue, and 25 cycles of RT-PCR was performed on cDNA using gene
specific primers. The full-length 1668 bp gene was amplified and isolated by gel
electrophoresis.

Construction of the rmAMH Expression Vector
The verified mAMH clone was maxiprepped with a Plasmid Maxi kit (Qiagen)

and the insert was excised from the TOPO vector with EcoRI and the expression vector
pQE81L (Qiagen) was cut at its multiple cloning site with BamHI and HindIII. Both the

insert and the vector were blunted by filling overhangs using T4 DNA polymerase

(Roche). The insert and vector were joined using a Rapid Ligation Kit (Roche) and
transformed into XLI-Blue supercompetent E. coli (Stratagene, La Jolla, CA). Clones
were miniprepped and analyzed by SmaI and BamHI digestion to show presence and

orientation of the insert, and four candidate clones were chosen from those that had the

insert in the correct orientation. The construct was designed such that rmAMH would be
expressed as an N-terminal 6xHis-tagged fusion protein. DNA sequencing confirmed the
presence of the mAMH gene in the correct orientation and in the same reading frame as
the 6xHis tag.
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Screening of Expression Clones

Four candidate clones were screened for protein expression by small scale culture
followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
western blot analysis. Starter cultures of each clone in 10 mL of lysogeny broth (LB)
medium with 100 |ig/mL ampicillin (amp) were growth overnight at 37oC in a shaker

incubator. After 16 hours, 100 |iL of each starter culture was used to inoculate a fresh 10

mL culture of LB/amp and incubated until the optical density at 600 nm (OD600) reached

0.5 (mid-log phase). At this point, expression was induced by adding isopropyl P-D-1thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The cultures were then

incubated for an additional 4 hours to allow protein expression. Culture samples were
taken both pre- and post-induction. Cells were pelleted by centrifugation and

resuspended in SDS-PAGE buffer and electrophoresed on a 15% Tris-HCl
polyacrylamide gel in a mini gel system (Bio-Rad, Hercules, CA) at 200 V for 45

minutes. The gel was stained with 0.05% Coomassie Brilliant Blue R-250 (Bio-Rad). A
second gel was run with the same samples under identical conditions for a western blot.

The gel was transferred to polyvinylidine fluoride (PVDF) membrane (Bio-Rad) in the
mini gel system overnight at 30 V. The membrane was blocked with proprietary

blocking agent (Qiagen) and stained with a horseradish peroxidase (HRP)-labeled 6xHis

antibody at 1:10,000 dilution for one hour at room temperature with gentle agitation. The
blot was washed with Tris-buffered saline (TBS)-tween solution and detection was

performed with electrochemiluminescent (ECL) reagents (Amersham, Piscataway, NJ)
and exposure to Hyblot CL autoradiography film (Denville Scientific, Holliston, MA).

The Coomassie-stained gel revealed a prominent band in the range of the predicted
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product size (62 kDa) in three of the four clones and only in the IPTG-induced lane from
each pair of samples. Western blot analysis confirmed that this band stained positively

for the 6xHis tag in all three samples. The identity of this protein as AMH was

subsequently confirmed by western blot using a primary polyclonal rabbit IgG specific
for a sequence near C-terminus of AMH (Abcam, Cambridge, MA) followed by detection

with an HRP-labeled mouse anti-rabbit IgG secondary antibody (Southern Biotech,
Birmingham, AL). One clone, designated AMHEX-3, was selected for use in all

subsequent work based on the robustness of expression.

Determination of Recombinant Protein Solubility
To determine whether to purify rmAMH from AMHEX-3 under native or

denaturing conditions, the product solubility was assessed. A small scale (50 mL) culture
was grown and induced with IPTG as described previously. The cells were pelleted by
centrifugation 4 hours post-induction. The pellet was resuspended in lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole) and lysed by freezing in dry ice/ethanol and

thawing in cold water. The pellet was then sonicated on ice using six cycles of 10

seconds on/10 seconds off at 300 W with a sonicator fitted with a microtip probe (Fisher
Scientific, Waltham, MA). Lysate was centrifuged at 10,000 x g for 25 minutes at 4oC.

Supernatant containing the soluble fraction was collected. The remaining insoluble
fraction was resuspended in lysis buffer and collected. Samples of each fraction were
mixed with SDS-PAGE buffer and run on a 10% Tris-HCl gel under denaturing
conditions and stained with Coomassie blue. The rmAMH band appeared in the
insoluble fraction.
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Expression of Recombinant mAMH
Recombinant mAMH was prepared from batch cultures and purified under

denaturing conditions. 500 mL LB/amp cultures were inoculated with 10 mL of LB/amp
overnight starter cultures and grown at 37oC in a shaker incubator until an OD600 of 0.5
was reached. Protein expression was then induced with IPTG at a final concentration of
1 mM. Cultures were then grown an additional 4.5 hours. Cells were pelleted by
centrifugation at 6,000 x g and frozen at -20oC for further processing.

Affinity Purification of Recombinant mAMH
Frozen cell pellets from 500 mL batch cultures were thawed on ice and
resuspended in 7.5 mL of denaturing lysis buffer (100 mM NaH2PO4, 10 mM Tris, 6 M

guanidine HCl, pH 8.0), split into two 250 mL centrifuge bottles and stirred at room

temperature for one hour. The centrifuge bottles were spun at 10,000 x g for 25 minutes

at 4oC to remove the insoluble debris from the lysate. The cleared lysate was then
transferred to 15 ml tubes and 350 |iL of a suspension of nickel nitrolotriacetic acid (Ni-

NTA) agarose (Qiagen) was added to each. The tubes were agitated slowly on an orbital

shaker at room temperature for one hour. The mixtures from both tubes was combined
and loaded on a poly-prep chromatography column (Bio-Rad) and the liquid phase was
allowed to flow through by gravity. The column was then washed twice with 4 mL
aliquots of wash buffer (100 mM NaH2PO4, 10 mM Tris, 8 M urea, pH 6.3). Elution was

first attempted by lowering the pH of the wash buffer to 5.9, which did not result in

significant recovery of AMH. The pH was then lowered to 4.5, which resulted in

successful elution of AMH from the column. For quality control purposes, samples were
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taken at each step of purification and run on denaturing SDS-PAGE gels and either

stained with Coomassie blue (Figure 2.1) or subjected to western blot (Figure 2.2)
analysis as described previously.

MW
(kDa)

165
80

Figure 2.1 SDS-PAGE of Recombinant mAMH. Denaturing SDS-PAGE was
performed on samples from Ni-NTA purification of rmAMH. Samples were run on a
15% Tris gel at 200 V for 45 minutes, then the gel was stained with Coomassie blue.
Kaleidoscope prestained marker was used to estimate molecular weight (MW). Samples
were taken pre-IPTG induction (uninduced) and at culture harvest (induced). Samples
from the column flow through and washes were collected (flow through; washes 1-2) and
from protein elution at pH 4.5 (elutions 1-4). Maximum protein was observed in elution
3. All eluted proteins ran at the expected MW of 62 kDa for rmAMH.
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Figure 2.2 Western Blot of Recombinant mAMH. Denaturing SDS-PAGE was
performed on samples from Ni-NTA purification of rmAMH. Samples were run on 15%
Tris gels at 200 V for 45 minutes, then the gel was transferred to polyvinylidine fluoride
(PVDF) membrane and stained with HRP-labeled AMH antibody and exposed to
electrochemiluminescence (ECL) reagents and captured on autoradiography film.
Kaleidoscope prestained marker was used to estimate molecular weight, and the ladder
positions were marked manually on the film (MW). Samples were taken pre-IPTG
induction (uninduced) and at culture harvest (induced). Samples from the cleared lysate,
column flow through, and washes were collected (cleared lysate; flow through; washes 1
2). Column elutions with buffer at pH 5.9 (elutions pH 5.9, four lanes) and at pH 4.5
(elutions pH 4.5, four lanes) were collected. Elutions at pH 4.5 were pooled and dialyzed
to water, then run on high performance liquid chromatography (HPLC) where the major
peak and shoulder were collected (final three lanes). The blot shows positive
identification of the recombinant protein as AMH. Greatest AMH detection occurred in
the induced sample, the elutions at pH 4.5, and the HPLC major peak. Detection in the
sample from AMH dialyzed to water was low due to the sample being highly dilute. All
AMH samples ran at the expected MW of 62 kDa.

HPLC Purification of Recombinant mAMH

For use in in vitro cell culture assays, affinity-purified rmAMH was further

refined by high performance liquid chromatography (HPLC) to increase purity and
remove any residual endotoxin (Dudley, et al., 2003). Aliquots of Ni-NTA purified
rmAMH in elution buffer were loaded onto a Beckman System Gold (Beckman Coulter,
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Brea, CA) fitted with a Vydac 214TP C4 column (Grace, Columbia, MD) and run on a
gradient from 100% water to 100% acetonitrile over the course of 50 minutes.
Recombinant mAMH eluted in a single major peak occurring between 32-36 minutes
(64-72% acetonitrile; Figure 2.3). The peak was collected and lyophilized on a Freezone
6 Plus lyophilizer (Labconco, Kansas City, MO). Dried protein was gently resuspended

in endotoxin-free water at 1 mg/mL. The identity of the eluted protein was confirmed
using western blot analysis (Figure 2.2) with anti-6xHis and anti-AMH antibodies as
previously described. Preparations were routinely tested for endotoxin by the Media

Preparation Core (Lerner Research Institute, Cleveland, OH) using the limulus

amoebocyte lysate (LAL) test and were consistently below the detectable threshold
(<0.05 EU/mL). Specificity control protein recombinant mouse P-casein (rmP-cas) used
for in vitro experiments was purified and tested in the same manner as rmAMH.
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33 Minutes
66% Acetonitrile

Figure 2.3 HPLC Profile of Recombinant mAMH. Ni-NTA-purified AMH was
further refined using HPLC to increase purity and remove endotoxin. AMH eluted as the
major peak centered at 33 minutes into a 50-minute linear gradient from 100% water to
100% acetonitrile. Acetonitrile content was approximately 66% at maximal elution.
Optical density was measured as absorbance at 280 nm.

Refolding of Recombinant mAMH

For mouse immunizations, Ni-NTA purified rmAMH in elution buffer was
dialyzed in a series of gradual steps to allow proper folding of the native conformation of
the protein to maintain solubility. Eluted fractions were combined and sealed inside
dialysis tubing with a molecular weight cutoff (MWCO) of 25 kDa (Spectrum

Laboratories, Rancho Dominguez, CA). The protein was first dialyzed against a large
volume of 8 M urea, pH 8.0. Then, in a series of ten steps, the buffer was diluted 1:2
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with deionized water. Finally, the protein was dialyzed against pure water, lyophilized,

and stored under vacuum as a dry powder until used.

Quantification of Recombinant Proteins
Each batch of recombinant protein was quantified using the Bio-Rad Protein
Assay, a modified version of the Bradford assay. Bovine serum albumin (BSA)
standards and samples were loaded at 10 |iL volumes on a 96-well MaxiSorp plate
(Nalge Nunc, Rochester, NY). 200 |iL of 1X dye reagent (Bio-Rad) was added and mixed

by pipetting and developed at room temperature for five minutes. Plates were then read

at 595 nm on a Victor2 spectrophotometer (Perkin Elmer, Waltham, MA) and standards
were plotted as absorbance vs. protein concentration using Origin 6.0 software

(OriginLab, Northampton, MA). Sample concentrations were determined from the linear
portion of the standard curve.

Mice and Immunization

Female C57BL/6J mice were purchased from The Jackson Laboratory (Bar

Harbor, ME). At 6-8 weeks of age, mice were immunized subcutaneously (s.c.) in the
abdominal flanks with 200 |iL of a water-in-oil emulsion of equal volumes of complete
Freund’s adjuvant (CFA; Difco Laboratories, Detroit, MI) containing 400 iig of dead
Mycobacterium tuberculosis H37RA (Difco) and water containing 1 mg/mL rmAMH.

Each mouse received a total of 100 Lg of rmAMH. Control mice were immunized with
an emulsion of CFA and water alone.
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T Cell Proliferation Assays

Ten days after immunization, mice were euthanized humanely with CO2
asphyxiation followed by cervical dislocation in accordance with institutional animal care
and use committee (IACUC) protocols. Axillary and inguinal lymph nodes were
dissected and macerated through 40 |im nylon mesh filters to make single-cell

suspensions. Cells were plated in Falcon 96-well tissue culture plates (Becton Dickinson,

Franklin Lakes, NJ) at 3.5 x 105 cells/well in Dulbecco's modified Eagle's medium
(DMEM; Media Preparation Core, Cleveland Clinic) supplemented with final

concentrations of 10% fetal bovine serum (FBS; Hyclone Labs, Logan, UT), 30 mM 4(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 2 mM L-glutamine, 1

mM sodium pyruvate, 100 U/mL penicillin and 100 |ig/mL streptomycin (Invitrogen).
Antigen was added to the wells in a tenfold log series for a final concentration of 0.01

|ig/mL to 100 |ig/mL. A specificity control protein, ovalbumin (OVA; Sigma-Aldrich,
St. Louis, MO) or recombinant mouse P-casein (rmP-cas), was added to control wells in
the same dilutions. Purified hamster anti-mouse CD3s (clone 145-2C11; BD
Biosciences, San Jose, CA) at 2 ug/mL was used as a positive control. Negative control

wells contained no antigen. Cultures were incubated at 37oC and 5% CO2 for 72 hours.

All wells were then pulsed with [methyl-3H] thymidine (Perkin Elmer) at 1 |iCi/well.
After 16 hours, plates were harvested with a 96-well plate harvester (Tomtec, Hamden,
CT) onto glass fiber filters (Perkin Elmer). Filters were dried, sealed in bags with

scintillation fluid, and counted with a Betaplate liquid scintillation counter (Perkin
Elmer).
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Responses by CD4+ and CD8+ T Cell Subpopulations

To assess the relative contributions of CD4+ and CD8+ T cells in the autoimmune

response, each subset was purified and tested in a proliferation assay as described above.

Ten days after immunization with rmAMH, lymph node cells (LNC) were harvested and
macerated through 40 ^m nylon mesh filters to make single-cell suspensions. T cell

subsets were enriched by positive selection using anti-CD4 or anti-CD8 coated magnetic

beads and passage through a magnetic-activated cell sorting (MACS) LS column in a
MidiMACS magnetic separator (Miltenyi Biotec, San Diego, CA). Enriched LNC were
plated in 96-well plated at 2.5 x 105 cells per well along with 4 x 105 irradiated syngeneic
splenocyte feeder cells. Feeder splenocytes were obtained from a naive C57BL/6J mouse

by maceration through a 40 |im nylon mesh filter and were pelleted at 1500 rpm and 4oC

in an Allegra X-14R centrifuge (Becton Dickinson) and resuspended in sterile water to
hypotonically lyse and eliminate red blood cells (RBCs). Lymphocytes were
immediately rescued by addition of 10% v/v 10X phosphate-buffered saline (PBS) to
restore isotonicity and washed again with 1X PBS. The cell suspension was then
subjected to 2000 rads of gamma radiation in a 137Cs irradiator (J.L. Shepherd &

Associates, San Fernando, CA). Unsorted, CD4+, and CD8+ T cells were cultured with
various doses of rmAMH and OVA in the same manner as previously described

proliferation assays. Proliferation was determined by incorporation of [methyl-3H]
thymidine as described above.
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FACS Analysis of Enriched CD4+ and CD8+ T cells

To determine the purity of the enriched T cell subpopulations, cells were co

stained with CD3, CD4, and CD8 antibodies and analyzed using flow cytometry. LNC
were washed with 1X PBS and resuspended in fluorescence-activated cell sorting

(FACS) staining buffer (1% BSA in PBS) and incubated for 45 minutes at 4oC with

PerCP-CD3s (clone 145-2C11), PE-CD4 (clone RM4-5), and FITC-CD8a (clone 53-6.7;
BD Biosciences). To minimize non-specific binding, cells were pre-incubated for 10
minutes at 4oC with Fc Block (anti-CD16/CD32; BD Biosciences). Cells were then fixed

with a 1% final concentration of paraformaldehyde and run on a FACScan flow
cytometer (Becton Dickinson). Data analysis was performed post-acquisition with
FlowJo version 7.0 (Flowjo, Ashland, OR). The lymphocyte populated was selectively

gated using forward and side scatter, and from that population, only the CD3+ cells were
analyzed for presence of CD4 or CD8.

Cytokine ELISA Assays

Ten days after immunization, mice were euthanized and lymph node cells were
collected in the same manner as for proliferation assays. Cells were cultured in complete

DMEM at 2.5 x 106 cells/mL in 24-well flat-bottom plates (BD Biosciences). Each well
contained 25 ug/mL of rmAMH (stimulated) or OVA (unstimulated) control in a total

volume of 2 mL per well. After 48 hours in culture, supernatants were collected and

cytokine levels were determined by sandwich enzyme-linked immunosorbent assay
(ELISA) in 96-well MaxiSorp plate (Nalge Nunc) using commercial recombinant mouse

cytokines (BD Biosciences) as standards. Cytokine capture/detection pairs were as
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follows: IL-2, clones JES6-1A12 and biotin JES6-5H4; IL-5, clones TRFK5 and biotin
TRFK4; IL-10, clones JES5-2A5 and biotin SXC-1; IL-17A, clones TC11-18H10 and

biotin TC11-8H4. Plates were coated with capture antibody at 4 pg/mL and blocked with

a solution of 3% BSA. Standards and samples were plated at a volume of 100 pL and
incubated overnight at 4oC. Biotinylated detection antibodies were used at 2 pg/mL.
Avidin-peroxidase was added and plates were developed using 2,2'-azino-bis(3ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate. For the IFNy assay, a
commercial optimized ELISA kit was used (OptEIA; Invitrogen) in a similar manner as
described above according to the manufacturer’s instructions. Plates were read at 405 nm
on a Victor2 spectrophotometer (Perkin Elmer) and standards were plotted as absorbance

vs. cytokine concentration using Origin 6.0 software (OriginLab). Sample concentrations
were determined from the linear portion of the standard curve.

Cytokine ELISpot Assays

Ten days after immunization, mice were euthanized and lymph node cells were
collected in the same manner as for proliferation assays. Single cell suspensions in

DMEM were plated at a density of 2 x 105 cells/well on 96-well PVDF filter plates
(Millipore Sigma, Burlington, MA) which had been pre-coated with the appropriate
cytokine capture antibody at 4 pg/mL and blocked with a solution of 1% BSA and 5%
sucrose in PBS. rmAMH antigen, as well as specificity control antigens rmP-cas and
OVA, were added to the appropriate wells at doses of 25 pg/mL and 50 pg/mL. Negative

control wells contained no antigen and positive control wells contained hamster anti
mouse CD3s (clone 145-2C11, BD Biosciences) at 2 pg/mL. After 72 hours of
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incubation at 37oC and 5% CO2, cells and media were aspirated and the plates were

washed and the appropriate biotinylated cytokine detection antibody was added at a
concentration of 2 ug/mL. Plates were then incubated overnight at 4oC. Cytokine
capture/detection pairs were as follows: IL-2, clones JES6-1A12 and biotin JES6-5H4
(BD Biosciences); IFNy, clones AN-18 and biotin R46A2 (eBioscience, San Diego, CA);
IL-5, clones TRFK5 and biotin TRFK4 (BD Biosciences); and IL-17, clones 17CK15A5
and biotin 1787 (eBioscience). After overnight incubation, plates were washed and 100
p.L/well streptavidin-alkaline phosphatase (Sav-AP) enzyme (R&D Systems,

Minneapolis, MN) solution was added at a working dilution of 1:60 in 1% BSA in PBS

per manufacturer’s instructions. Plates were then incubated for 2 hours at room

temperature and washed again. 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue

tetrazolium (BCIP/NBT) solution was added to all wells at 100 pL/well and the plate was

incubated in the dark at room temperature for 20-30 minutes until spots were clearly
visible. Plates were then rinsed with deionized water and air-dried overnight at room
temperature and scanned using an ImmunoSpot plate reader (CTL, Shaker Heights, OH).

Data were collected and analyzed using ImmunoSpot 4.0 software (CTL).

qRT-PCR Analysis
At 4 weeks, 8 weeks, and 10 months after immunization, mice were euthanized as

previously described and tissues were collected for mRNA expression analysis. Ovary,
spleen, heart, liver, kidney, and brain samples were removed immediately following

perfusion and placed in RNAlater preservative (Sigma-Aldrich) and stored at -20oC until
use. Samples were processed in Trizol reagent (Invitrogen) using a Tissuemaster 240
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homogenizer (Omni International, Kennesaw, GA) until completely dissociated. RNA

was then extracted in chloroform and tubes were centrifuged at 12,000 x g for 15 minutes

at 4oC. The upper aqueous layer containing the RNA was carefully transferred to a fresh
tube and precipitated using isopropanol. RNA was pelleted by centrifugation at 12,000 x

g for 15 minutes at 4oC, and the pellet was then washed with 70% ethanol made with

diethyl pyrocarbonate (DEPC)-treated water. The RNA was then centrifuged at 7,500 x g
for 7 minutes at 4oC and the supernatants decanted. RNA pellets were allowed to air-dry
for 10-15 minutes then resuspended in 30 |iL nuclease-free water. To ensure that the

RNA was not contaminated with genomic DNA, DNAse treatment was immediately
performed using a DNA-free kit (ThermoFisher Scientific, Waltham, MA) according to
the manufacturer’s instructions. Briefly, samples were treated with recombinant DNAse

at 37oC for 30 minutes, then the enzyme was inactivated with DNAse inactivation buffer
for 1.5 minutes at room temperature. Samples were then centrifuged and transferred to

fresh tubes and quantified using a Nanodrop 2000 spectrophotometer (ThermoFisher).
cDNA was then made from the mRNA using a Superscript III first strand synthesis kit
(Invitrogen) according to the manufacturer’s instructions. Briefly, RNA was incubated

with oligo dT primer at 65oC for 5 minutes, then placed on ice for one minute and

centrifuged. The enzyme mix containing reverse transcriptase was added, and the
mixture was incubated for 50 minutes at 50oC, and then transferred to ice. The cDNA

was quantified using a Nanodrop 2000. Quantitative real-time polymerase chain reaction
(qRT-PCR) analysis was then performed using a StepOne Plus Real-Time PCR System

(Applied Biosystems, Forest City, CA) using primer pairs specific for mouse IL-ip,
TNFa, IFNy, IL-2, IL-10, IL-17A, and AMH (Table 2.2) according to the manufacturer’s
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protocol. Briefly, for each well, 400 ng of cDNA, 0.5 |1M primers, and 1X SYBR Green
Master Mix (Applies Biosystems) were added to a MicroAmp Fast Optical 96-well plate

(Applied Biosystems) and run for a total of 40 cycles with an annealing/extension
temperature of 60oC. Melt curves were automatically performed at the end of each run to

ensure the integrity of the data. The quality of each assay was verified by electrophoresis

of the final qPCR products on agarose gels. The expression of the gene target in each
sample was first normalized to the expression of the endogenous control P-actin for that
sample (ACt). Means of samples from AMH-immunized mice were then calculated

relative to the means of CFA-immunized controls (AACt) and the results plotted as the
fold change in gene expression (2A-AACt).
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Amplicon
Length
(bP)

Target

Primer

mTNFa1

Forward
Reverse

CGAGTGACAAGCCTGTAGCC
GTGGGTGAGGAGCACGTAGT

209

mIL-1p2

Forward
Reverse

AAGGAGAACCAAGCAACGACAAAA
TGGGGAACTCTGCAGACTCAAACT

213

mIFNY1

Forward
Reverse

GGATATCTGGAGGAACTGGCAA
TGATGGCCTGATTGTCTTTCAA

110

mIL-21

Forward
Reverse

GCAGGCCACAGAATTGAAAG
TCCACCACAGTTGCTGACTC

207

mIL-103

Forward
Reverse

TGGCCCAGAAATCAAGGAGC
CAGCAGACTCAATACACACT

264

mIL-17A2

Forward
Reverse

AAGGCAGCAGCGATCATCC
GGAACGGTTGAGGTAGTCTGAG

150

mAMH

Forward
Reverse

CAGGCCCCCAGGTCACAGTC
AGCGGGAATCAGAGCCAAATAGAA

213

mP-actin 1

Forward
Reverse

GGTCATCACTATTGGCAACG
ACGGATGTCAACGTCACACT

133

Sequence (5’- 3’)

1 (Sakalar, et al., 2015)
2 (Mazumder, et al., 2017)
3 (Kawane, et al., 2010)
Table 2.2 Primers for qRT-PCR Analysis of Gene Expression. Primer pairs specific
for signature cytokines, AMH, and P-actin endogenous control were used to assay
relative gene expression in mouse ovarian tissues using quantitative real-time PCR. All
sequences are in 5' to 3' orientation. Validated primer sequences were obtained from
published references as noted.
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Immunohistochemistry
At 4, 8, and 12 weeks after immunization, mice were euthanized by CO2

asphyxiation and perfused with PBS for tissue collection. Ovaries were dissected and
fixed in methanol fixative (60% methanol, 30% double-distilled deionized water, 10%
acetic acid), embedded in paraffin, and sectioned at 5 |im thickness. For

immunostaining, a rabbit ImmunoCruz kit (Santa Cruz Biotechnology, Dallas, TX) was
used according to the manufacturer’s specifications. Briefly, slides were de-paraffinized
by heating to 50oC for 10 minutes, followed by washes in xylene, 100% ethanol, 95%
ethanol, and finally double-distilled deionized (DDD) water. Antigens were unmasked

by submerging in citric acid buffer (10 mM sodium citrate, pH 6.0) for 30 minutes in a

non-pressurized steamer, then allowed to cool to room temperature. Slides were blocked
with 5% normal donkey serum, and then incubated overnight at 4oC with polyclonal

rabbit anti-mouse CD3 (Abcam) at 1:250 dilution. Slides were then incubated for 30

minutes with an HRP-labeled goat anti-rabbit IgG and developed using a 3,3'diaminobenzidine (DAB) substrate. Slides were then washed in DDD and counterstained
with Harris hematoxylin (Electron Microscopy Sciences, Hatfield, PA) and dehydrated
with washes of 95% ethanol, 100% ethanol, and finally xylene. Slides were coverslipped
with Permount medium (Fisher Scientific). Similarly, fixed ovarian sections at 4 and 8

weeks after immunization were unmasked with Trilogy reagent (Millipore Sigma) and
stained with affinity-purified polyclonal rabbit anti-mouse C4d (a gift from the Baldwin
Lab, Cleveland Clinic, Cleveland, OH) at 1:500 dilution and counterstained with

hematoxylin (Murata, et al., 2007). All slides were scanned at 20X and imaged using an
SCN400 automated slide scanner (Leica Biosystems, Buffalo Grove, IL).
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Serum Autoantibody Isotyping
At 4 weeks, 8 weeks, 12 weeks, and 10 months after immunization, blood was

collected via terminal cardiac puncture with a 1 mL syringe with a 22 gauge 1” needle
(Becton-Dickinson) under general anesthesia using a vaporizer (Ohmeda, Madison, WI)

delivering a constant supply of oxygen with 2.5% isoflurane (Baxter, Deerfield, IL).
After blood collection, mice were euthanized via cervical dislocation in accordance with

IACUC protocols, and blood was allowed to clot for one hour at room temperature, then

transferred to 4oC overnight. After 16 hours, the blood samples were centrifuged for one
minute at 2,500 x g at 4oC, then sera were carefully transferred to clean microcentrifuge

tubes. Tubes were then centrifuged at 1,500 x g for 10 minutes at 4oC, and again
transferred to clean microcentrifuge tubes. Cleared sera were then transferred to clean
tubes and stored at -20oC until use. Sera were tested for the presence of AMH-specific

IgG isotypes using a Mouse Typer Sub-Isotyping Kit (Bio-Rad) according to the
manufacturer’s specifications. Briefly, HPLC-purified rmAMH or rmP-cas was plated in
96-well flat bottom MaxiSorp plates (Nalge Nunc) at 10 |ig/mL in a volume of 50 |iL
PBS and incubated overnight at 4oC. Wells were washed and blocked with 1% BSA in
PBS for 1 hour at room temperature. Serum samples were diluted serially with 1% BSA

in a 1:2 scheme from 1/256 to 1/8192 and added to the plate in duplicate wells in 100 |iL
volumes and incubated overnight at 4oC. Negative control wells contained diluent alone
and positive control wells contained a rabbit polyclonal mAMH (Abcam) antibody at

1:1000 dilution. Plates were washed and pre-diluted rabbit anti-mouse IgG isotype
detection antibodies added: IgG1, IgG2a, IgG2b, and IgG3. Plates were incubated for one

hour at room temperature, then washed again. Wells were then treated with horseradish
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peroxidase (HRP) conjugated goat anti-rabbit IgG and exposed to peroxidase substrate
solution for 30 minutes and absorbance at 405 nm was measured with a Victor2 1450

spectrophotometer (Perkin Elmer). Mean absorbances for each isotype were plotted vs.

antibody titer.

Serum Hormone ELISAs

To evaluate circulating levels of AMH in the bloodstream, blood from mice

immunized with rmAMH or CFA was collected via terminal cardiac puncture as
previously described at 10 months after immunization. Sera were kept frozen at -20oC

until use and evaluated for AMH levels using a commercially-available mAMH
competitive ELISA kit (Cusabio, College Park, MD) according to the manufacturer’s
instructions. Briefly, serum samples were thawed and diluted 1:3 with PBS, then added

in duplicate to wells in a 96-well plate pre-coated with capture antibody. AMH standards
supplied with the kit were also added in separate wells in duplicate. The volume of all
samples and standards was 50 |iL. Unlabeled standards and samples competed with
HRP-labeled AMH for 1 hour at 37oC. After a final wash, 3,3‘,5,5‘-tetramethylbenzidine

(TMB) substrate was added and the plate was developed for 15 minutes at 37oC. 50 |iL

of stop solution was then added to the plate to halt development, and the absorbance at
450 nm was read on a Victor2 spectrophotometer (Perkin Elmer). Means of the standards

were plotted vs. absorbance, and the mean AMH concentrations of samples were

determined from the linear portion of the standard curve. Serum FSH levels were
similarly assessed at 8 weeks and 10 months after immunization using a commercial non

competitive sandwich ELISA kit (Aviva Systems Biology, San Diego, CA) according to
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the manufacturer's instructions. Briefly, serum samples were diluted 1:100 with kit

diluent and added in duplicate to wells in the 96-well assay plate pre-coated with capture
antibody along with along with the kit FSH standards in a volume of 100 |1L and

incubated for two hours at 37oC. The plate was then washed and 100 |iL of biotinylated
detection antibody was added and the plate was incubated for one hour at 37oC. The

plate was washed again and 100 |iL of avidin-HRP conjugate was added and the plate
was again incubated for one hour at 37oC. After a final wash, TMB substrate was added
and the plate was developed at 37oC for 15 minutes in the dark. The reaction was halted
with kit stop solution and the absorbance at 450 nm was read, the standard curve was
plotted, and sample values determined in the same manner as described for the ELISA for

AMH.

Fertility Assessments
To evaluate the impact of AMH autoimmunity on fertility, 8-week old female

mice were immunized with rmAMH or CFA alone and serially mated to the same agematched C57BL/6J males for four mating cycles (Figure 2.4). Matings began 14 days
after immunization, and females were rested for two weeks between parturition and the

next mating cycle. Mice were checked daily for litters. Total litter weights, individual
pup weights, and numbers of pups per litter were assessed at birth.
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Figure 2.4 Fertility Assessment Mating Scheme. To assess fertility, female C57BL/6J
immunized with either AMH or CFA control were mated with normal age- and strainmatched males. Males mated with equal numbers of AMH and CFA immunized mice.
Each male mated with the same females for every mating round.

Follicle Quantification and Ovary Measurements
At 4 weeks, 8 weeks, and 10 months after immunization, mice were euthanized,

perfused with PBS, and ovaries were dissected and weighed. Ovaries were then fixed in
methanol fixative (60% methanol, 30% DDD water, 10% acetic acid) and embedded in

paraffin and serially sectioned completely through the organ. Every tenth 5 pm section

was mounted to avoid counting any follicle more than once. Sections were stained with
hematoxylin and eosin (H&E) and slides were imaged using a SCN400 automated slide
scanner (Leica Biosystems). Images were analyzed in ImagePro 7.0 software (Leica
Biosystems) and follicles were manually tagged and counted using the following criteria:
small, an oocyte surrounded by a single layer of granulosa cells; medium, an oocyte
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surrounded by 2-3 layers of granulosa cells; large, an oocyte surrounded my more than
three layers of granulosa cells and/or the presence of antra (Figure 2.5). Involuted
follicles as well as any large follicles showing signs of involution and/or pyknotic nuclei
were considered atretic. Corpora lutea were identified as large, light-colored bodies with

a slim central cavity containing a blood clot. The area of each serial section analyzed
was measured by manually outlining the perimeter in ImagePro. The mean area of each
ovary was determined as the average area of the four largest consecutive sections. Ovary
weights were normalized to body weight just prior to euthanization.

Figure 2.5 Follicle Quantification Scheme. For each H&E stained ovarian section,
follicles were quantified according to morphology. Small, medium, large, and atretic
follicles, as well as corpora lutea were counted and ovarian measurements were taken
manually using ImagePro software.
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Estrous Cycle Staging

Four weeks after immunization with rmAMH or CFA, vaginal smears were taken
at the same time daily for a total of 52 consecutive days by flushing the vagina with 20
|iL of sterile PBS and transferring to a glass slide. Slides were air-dried, then fixed in

100% methanol and allowed to dry. Slides were then stained with methylene blue in
9.5% ethanol, then washed with DDD water and then 75% ethanol. Slides were air-dried
and coverslipped with Permount (Fisher Scientific). Slides were examined with light

microscopy and estrous stage was determined as follows: proestrus, predominantly round
nucleated epithelial cells with presence of leukocytes; estrus, cornified non-nucleated
epithelial cells with absence of leukocytes; metestrus, roughly equal numbers of cornified
epithelial cells and leukocytes; diestrus, a predominance of leukocytes (80-100%; Figure
2.6).
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Day 1 - PROESTRUS

Day 2 - ESTRUS

Day 3 - METESTRUS

Day 4 - DIESTRUS

Figure 2.6 Estrous Cycle Staging Scheme. Vaginal samples were collected at the same
time daily, smeared on slides, methanol fixed, and stained with methylene blue. Slides
were examined under the microscope and estrous stage was determined by the relative
numbers of cell types and their morphologies. Panels represent the typical appearance of
each stage, each of which lasts approximately one day. Scale bar represents 100 |im.
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Passive Transfer of Autoimmunity
To assess the contributions of various components of the immune system to the

observed phenotype, passive transfer was performed. Eight-week-old female C57BL/6J
donor mice were actively immunized s.c. with 100 jug rmAMH or OVA control as
previously described. After four weeks, spleens were harvested and single-cell
suspensions were made. Suspensions from each immunizing antigen were pooled and

populations of CD4+ T cells and B cells were enriched using MACS separation as

previously described with CD4-specific and B220-specific beads, respectively (Miltenyi
Biotec). Purities of enriched populations were confirmed using FACS analysis as

previously described. B cells were washed with PBS and immediately transferred by

intraperitoneal (i.p.) injection to naïve age and sex matched syngeneic recipients, with
each mouse receiving a total of 2 x 107 cells. Prior to transfer, CD4+ enriched T cells

were cultured and activated in 24-well plates with syngeneic irradiated splenocyte feeder

cells for four days with HPLC-purified rmAMH or OVA recall antigen at 25 |ig/mL. T
cells were then harvested, washed with PBS, and injected i.p. into naïve recipients at 2 x
107 cells per mouse. In addition, blood from mice immunized with rmAMH or OVA was
collected at 4 weeks via terminal cardiac puncture as previously described. Sera were

transferred to naïve recipient mice via intravenous (i.v.) tail vein injection using a 1 mL

syringe with a 30 gauge needle (Becton-Dickinson). Each mouse received a total of four
injections of 200 |1L serum every third day. Seven days after initial transfer, mice were
evaluated every day for estrous cycle stage using vaginal smears as previously described.
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Statistical Analyses

The unpaired Student's t-test was used to analyze differences in fertility, estrous
cycle, follicle numbers, gene expression, and hormone levels between mice immunized

with CFA containing rmAMH and control mice immunized with CFA alone.
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CHAPTER III

RESULTS

Immunization with AMH Elicits a Robust Antigen-Specific T Cell Response
To determine the T cell response to rmAMH, ten days after immunization with

100 gg rmAMH in CFA, inguinal and axillary LNC were cultured in the presence of
antigen over a wide logarithmic dose range for 72 hours. Cells were radiolabeled with

tritiated thymidine, and the degree of cell division was expressed as the stimulation index
(SI), defined as the counts per minute (cpm) of sample divided by the cpm of negative

control wells with no antigen. The results show that rmAMH elicited a significant T cell
response (>20 SI units) at 10 gg/mL and an extremely robust T cell response (>100 SI

units) at 100 gg/mL (Figure 3.1). Not only was this response dose-dependent, but it was
antigen-specific, as there was no measurable response to the immunologically-irrelevant

antigen OVA across the entire dose range.
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FIGURE 3.1 T cell proliferation response to AMH. Ten days after immunization with
rmAMH, LNC were harvested and tested in culture for response to antigen. T cells
showed a robust, dose-dependent response to HPLC-purified rmAMH, but not to the
irrelevant control antigen OVA. Error bars represent ±SEM.

AMH-reactive T Cells are Primarily of the CD4+ Phenotype
To further characterize the phenotype of AMH-reactive T cells, ten days after

immunization with rmAMH, LNC were harvested and enriched for either CD4+ or CD8+

T cells by positive selection using MACS magnetic separation beads. To verify the
purity of the enriched populations, flow cytometry was performed on samples using
fluorochrome-tagged antibodies specific for mouse CD4 and CD8. Analysis of results

confirmed high homogeneity of the enriched populations, with CD4+ cells >98% pure
and CD8+ >97% pure (Figure 3.2). Enriched and unsorted cells were then cultured for
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72 hours in the presence of antigen and with irradiated syngeneic splenocyte feeders, and

T cell proliferation was measured as previously described with radiolabeling. The data
showed a robust response to rmAMH in the unsorted LNC, which was greatly enhanced

in the enriched CD4+ population (Figure 3.3). In contrast, the CD8+ population showed
little response to cognate antigen. In all cases, positive responses were dose-dependent.

No significant proliferation was observed in response to the irrelevant control antigen
OVA, confirming antigen-specificity. These data indicate that the T cell immune

response to AMH is primarily of the CD4+ phenotype, which represents the T helper

(TH) subset. The responses elicited by CD4+ Tells are restricted to antigens presented by
major histocompatibility (MHC) class II molecules, which suggests that this is the

primary form of T cell activation following immunization with rmAMH.
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Figure 3.2 Flow Cytometry Analysis of Enriched CD4+ and CD8+ T Cells. LNC
were harvested from rmAMH-immunized mice and analyzed by flow cytometry before
(unsorted, left) and after (MACS enriched, right) positive selection using CD4 or CD8
MACS beads. Cells were triple-stained with fluorochrome-labeled antibodies to CD4,
CD8, and the T cell marker CD3. The target population was gated using forward and
side scatter, and further gated on the CD3+ population. After enrichment, the purity of
CD4+ and CD8+ increased from 56.3% to 98.8% and from 33.9% to 97.6%, respectively.
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Figure 3.3 Proliferation Assays. Ten days after immunization with rmAMH, LNC
were harvested and a portion were purified by MACS positive selection for CD4 or CD8.
Cells were cultured for 72 hours with rmAMH or OVA control on a monolayer of
irradiated syngeneic splenocyte feeders. Unsorted splenocytes and CD4+ T cells showed
robust, dose-dependent, antigen-specific responses. A negligible response was observed
in the CD8+ population. Error bars represent ±SEM.

AMH Immunization Elicits a Type-1/Type-17 Cytokine Profile
To assess the cytokine profile of the T cell response to AMH, ten days after

immunization with rmAMH, LNC were cultured at 2.5 x 106 cells/mL in 24-well flat

bottom plates in the presence of 25 ^g/mL rmAMH or OVA negative control for 48
hours. Supernatants were then collected and analyzed by sandwich ELISA for a panel of

type-1, type-2, and type-17 cytokines. The rmAMH-stimulated wells showed a

predominance of the definitive type-1 cytokine JFNy, as well as significant expression the
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type-1 associated T cell growth factor IL-2 (Figure 3.4). In addition, there was robust

expression of the archetypal type-17 cytokine IL-17. There was no measurable
production of the type-2 cytokines IL-4 or IL-5, and only a trivial amount of the type-2

cytokine IL-10 was detected. There was no observable cytokine production in wells

stimulated with the OVA control. Taken together, these data indicate that immunization
with AMH elicits a strong, antigen-specific type-1/type-17 cytokine profile, which is
typical of an autoimmune response (Raphael, et al., 2015).

Figure 3.4 Cytokine ELISA Profile of AMH-Specific T Cells. Ten days after
immunization with rmAMH, LNC were cultured in the presence of HPLC-purified
rmAMH or OVA control. Culture supernatants were collected and tested for a panel of
cytokines by sandwich ELISA. Results indicate a strong antigen-specific type-1/type-17
immune response. Error bars represent ±SEM.
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ELISpot Analysis of Type-1/Type-17 T Cell Frequencies
To further evaluate the type-1/type-17 profile evident in the culture supernatants

by ELISA, ELISpot analysis was performed to assess the frequencies of T cells secreting

IL-2, IFNy, IL-5, and IL-17. Ten days after immunization with rmAMH, LNC were

harvested and seeded at 2 x 105 cells/well in 96-well PVDF filter plates. Plates were

cultured for 72 hours in the presence of 25 ug/mf or 50 ug/mf antigen. For these
experiments, mouse P-casein (rmP-cas), a recombinant protein prepared from E. coli
using the same protocol for generating rmAMH, was used in addition to the OVA control

to rule out non-specific stimulation from bacterial contaminants. As in the ELISA

analysis, the dominant cytokine secreted was IFNy; T cells producing this cytokine

exhibited a frequency of over 100 cells per million at the 50 ug/mf dose (Figure 3.5).
Also congruent with the ELISA results, substantial IL-2 and IL-17 activity was detected,
with no measurable contribution from cells secreting IL-5. No significant responses were
observed with either control protein, affirming once again that the responses to rmAMH
are antigen-specific. Moreover, in accord with T cell proliferation assays, antigen

specific responses were positively dose-dependent. Taken together, these data reinforce
the type-1/type-17 characterization of the AMH immune response.
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Figure 3.5 Cytokine ELISpot Profile of AMH-Specific T Cells. Ten days after
immunization with rmAMH, LNC were cultured in ELISpot plates for 72 hours in the
presence of antigen or control and tested for the frequencies of T cells producing
cytokines IL-2, JFNy, IL-17, and IL-5. Data are expressed as spot-forming units (SFU)
per million cells at each dose for each recall antigen. Results indicate a dose-dependent
antigen-specific type-1/type-17 response. Error bars represent ±SEM.

qRT-PCR Analysis Reveals Expression of Type-1/Type-17 Inflammatory Genes

Multiple lines of in vitro evidence have shown that AMH immunization produces

a robust type-1/type-17 T cell response that is characteristic of autoimmunity. To assess
the AMH immune response at a molecular level in the host, ovarian tissues were
harvested from mice at 4 weeks, 8 weeks, 12 weeks, and 10 months after immunization

with rmAMH or CFA. Expression of a panel of signature cytokines (Table 2.2) was

evaluated using quantitative real-time RT-PCR (qRT-PCR). Each sample was first
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normalized to its endogenous P-actin control, and gene expression for each target
cytokine in the AMH-immunized mice was quantified relative to age-matched CFA-

immunized controls. The data reveal a pattern of transient initial upregulation of the

innate inflammatory cytokines IL-1P and TNFa, with TNFa expression being the most
prominent, peaking early and subsiding by 12 weeks. The inflammatory type-1/type-17
cytokines IFNy and IL-17 were also expressed abundantly from 4 weeks through 12
weeks. Very little expression of the type-2 cytokine IL-10 was observed at any time
point. This predominantly type-1/type-17 inflammatory in vivo tissue profile is

consistent with in vitro ELISA and ELISpot assays. IL-2, while detected in minor
quantities in vitro in LNC harvested ten days after immunization, was generally not

observed in significant quantities in the tissues examined at 4 weeks and beyond. This is

probably due to the role of IL-2 as an early-expressed factor driving the differentiation of
naive T cells to effector cells (Liao, et al., 2011). Expression of all cytokines had

subsided by 10 months, indicating a late waning of the cellular immune response.
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Figure 3.6 qRT-PCR Inflammatory Marker Profile of Ovarian Tissue. qRT-PCR
analysis was performed on ovarian tissue harvested from mice immunized with rmAMH
or CFA. Data were normalized to internal P-actin controls and plotted relative to agematched CFA controls. Innate inflammatory cytokines IL-1P and TNFa were expressed
early and transiently. Consistent with in vitro assays, significant upregulation of type-1
and type-17 cytokines was observed, while type-2 cytokine IL-10 remained low. Error
bars represent ±SEM.
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Immunohistochemistry Shows Mild Transient T cell Infiltration of Ovarian Tissues
To further explore the effect of the AMH immune response in vivo,

immunohistochemistry (IHC) was performed on tissue sections from the ovaries of mice

4, 8, and 12 weeks after immunization with rmAMH or CFA. Methanol-fixed paraffin-

embedded sections were immunostained with polyclonal rabbit anti-mouse CD3 and

analyzed by light microscopy for evidence of T cell infiltration. At 4 weeks, a mild
diffuse CD3+ infiltration was detected in sections from mice in the AMH group (Figure

3.7 A). These cells were primarily found associated with granulosa cells of follicles
(black arrows). No infiltrates were detected in sections from CFA control mice (Figure

3.7 B). This early infiltration was transient, as no significant infiltrates were observed in
CD3+ sections at 8 and 12 weeks (data not shown). Complement activation was absent
as evidenced by negative staining for complement component 4d (C4d; Appendix, Figure

S1). No gross pathology or anatomical abnormalities were observed in the tissues of any

of the samples in either group.
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Figure 3.7 CD3+ T Cell Infiltration of Ovarian Tissue. Sections of ovaries from mice
immunized with rmAMH or CFA were immunostained with CD3 antibody and analyzed
by light microscopy. (A) At 4 weeks, mild diffuse T cell infiltrates were evident (black
arrows). (B) No infiltrates were observed in immunostained sections of CFA controls.
Scale bar represents 50 ^m.
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AMH Immunization Produces Long-Lasting High Titers of Antigen-Specific

Autoantibodies
To this point, a robust type-1/type-17 cellular immune response to immunization

with rmAMH has been characterized. To assess whether AMH immunization also
induces a humoral response, sera were obtained from mice by cardiac puncture at 4
weeks, 8 weeks, 12 weeks, and 10 months after immunization with AMH or CFA control.
Sera were diluted with PBS in a 1:2 series and tested by ELISA for the presence of

AMH-specific antibodies for each IgG subclass. At 8 weeks, mice exhibited a robust

humoral response to AMH primarily of the IgG1 and IgG2b isotypes, with titers detectable

at 1/8192 dilution (Figure 3.8 A). These positive reactions were antigen-specific, as there
was no significant response of any IgG isotype to either PBS alone or the control antigen
rmP-casein. Moreover, sera from mice immunized with CFA alone did not react to AMH

or controls, even at the highest serum concentration of 1/256 (Figure 3.8 B).

The C57BL/6J mouse is unusual in that the gene for IgG2a is absent; it instead
produces an IgG2c isotype. Accordingly, there was no significant IgG2a detected in any
sample (data not shown). To date, there are no commercially available isotyping reagents
to specifically detect IgG2c (Martin, et al., 1998). No IgG3 was detected in any sample.
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Figure 3.8 Serum AMH Autoantibody Titers at 8 Weeks. Serum was obtained from
cardiac blood and tested for antibody response to rmAMH and controls. (A) Mice
immunized with rmAMH demonstrated high IgG1 and IgG2b titers at 8 weeks in response
to rmAMH but not in response to PBS or rmP-casein controls. (B) Mice immunized with
CFA alone showed no response to controls or rmAMH even at the maximum
concentration of 1/256. Titers represent 1:2 dilutions of serum in PBS from 1/256 to
1/8192. Serum dilution for PBS and rmP-casein controls is 1/256. For all titers n=4.
Error bars represent ±SEM.

This signature humoral response was also consistently detected at 4 and 12 weeks
after immunization, and was found to persist at high levels at 10 months (Figure 3.9). At
this late stage, IgG1 levels dropped by approximately half, while IgG2b remained stable.
At all time points tested, responses were vigorous and antigen-specific, indicating that

AMH immunization generated a robust and long-lasting antibody response.
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SERUM TITER

Figure 3.9 Long-Term Serum AMH Autoantibody Titers. Serum was obtained from
cardiac blood and tested for antibody response to rmAMH and controls. A strong
consistent IgG1 and IgG2b profile was observed at (A) 4 weeks, (B) 8 weeks, (C) and 12
weeks after immunization with rmAMH. (D) This response was long-lived and
detectable at 10 months. At this late stage, titers of IgG1 fell approximately 50%, while
IgG2b remained steady at high levels. Titers represent 1:2 dilutions of serum in PBS from
1/256 to 1/8192. Serum dilution for PBS and rmP-casein controls is 1/256. Error bars
represent ±SEM.

Immunization with AMH Extends Fertility

A strong cellular and humoral autoimmune response has been demonstrated in
mice immunized with AMH, an ovarian regulatory hormone. To assess the effect of this

immune attack on fertility in vivo, a serial mating study was conducted. Two weeks after
immunization with rmAMH in CFA or with CFA alone, female mice were serially mated
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to age- and strain-matched males for four breeding cycles. Males mated with equal

number of AMH and CFA control mice, and were mated to the same females for each
round. Initially, mice in both groups regularly produced litters of average size, and there
were no significant differences in the numbers of pups in each litter. Over the duration of
this long-term fertility study, a natural and gradual decline in fertility was observed in

both groups. However, this decline appeared to be slowed in the AMH-immunized mice
(Figure 3.10), and by the fourth mating, when the mice were approximately ten months of
age, the mean numbers of pups per litter in the AMH group was more than double the

number in the CFA control group, averaging 7.0 and 3.3 pups per litter, respectively.
This difference was highly statistically significant (P < 0.006).
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Mating Round (Days After Immunization)
Figure 3.10 Mean Numbers of Pups Per Litter. Female mice immunized with
rmAMH or CFA control were mated for four rounds with the same males. Numbers of
pups in each litter were assessed at birth. The CFA group showed a gradual natural
decline in fertility over time. In the AMH group, this decline was significantly
moderated, resulting in a two-fold greater pup production by the fourth round. Error bars
represent ±SEM.

This disparity in fertility decline was also evident when litters were compared by total

weights instead of numbers of pups (Figure 3.11 A) which yields a nearly identical result
and was also highly significant (P < 0.007). Importantly, throughout the entirety of the

study, mice in both groups consistently gave birth to healthy pups of normal weight, and
there were no significant differences in mean pup birth weights between the groups or
between mating rounds (Figure 3.11 B).
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Figure 3.11 Mean Weights of Litters and Birth Weights of Pups. Female mice
immunized with rmAMH or CFA control were mated for four rounds with the same
males. Weights of entire litters and individual pups were assessed at birth. (A) Mean
weights of litter declined dramatically in the CFA group, but were relatively unchanged
in the AMH group. (B) Weights of pups at birth were normal in both groups at each
round, confirming that litter weight differences were due to differences in numbers of
pups and not due to pup weight disparities. Immunization of the female with rmAMH
did not alter pup weight, and no other abnormalities in pups were observed. Error bars
represent ±SEM.

It is important to note that litter size and weight assessments by definition include only
fertile mice producing litters. Equally critical is the proportion of total mice that are
fertile at each mating round. These data show that in addition to maintaining a greater

level of fertility in terms of litter sizes, AMH immunization substantially preserves the

number of fertile females producing litters over time (Figure 3.12). This appraisal yields

a very similar profile to the litter size and weight data, with roughly equal proportions of
females producing litters in the first two rounds, and a marked difference in fertility
becoming evident in the latter two rounds. Again, fertility in aged mice was extended in
the AMH-immunized group. This enhancement is also evident in the raw data (Table
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3.1). Both groups showed similar attrition due to natural aging factors that were not

associated with treatment.

Figure 3.12 Percentage of Mice Producing Litters. Female mice immunized with
rmAMH or CFA control were mated for four rounds with the same males. Over time, a
natural decline in fertility resulted in fewer females producing litters. The AMH group
exhibited enhanced fertility with a greater percentage of mating females producing litters
in the latter two rounds.
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Mating Round
Immunogen

1

2

3

4

CFA Alone

6/8

7/7

3/6

3/6

AMH/CFA

7/8

7/8

6/8

5/7

Table 3.1 Proportion of Fertile Females in Each Mating Round. Female mice
immunized with rmAMH or CFA control were mated for four rounds with the same
males. Over time, a natural decline in fertility resulted in fewer females producing litters.
The AMH group exhibited enhanced fertility with a greater percentage of mating females
producing litters in the latter two rounds. In both groups, there was roughly equal
attrition due to natural causes not associated with treatment.

Immunization with AMH Conserves Ovarian Follicles
To evaluate the effects of AMH immunization on ovarian follicles, histologic

serial section analysis was performed. Ovaries dissected from mice at 4 weeks, 8 weeks,
and 10 months after immunization with rmAMH or CFA were weighed, fixed in

methanol, and embedded in paraffin. Ovaries were then serially cross-sectioned through
the entire organ, with every tenth section mounted and stained with H&E. This allowed

active follicles in three-dimensional space to be classified and tallied without counting

any follicle more than once. Sections were digitally scanned, the images were measured,
and follicles were manually identified and tagged in software. A grand total of 662

sections were analyzed. The profiles of ovary weights (Figure 3.13 A) and cross
sectional area (Figure 3.13 B) are remarkably similar, showing consistent similar metrics

in both groups at 4 and 8 weeks after immunization, but exhibiting a dramatic drop to
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approximately half their values at 10 months in both groups. These data are consistent

with the natural atrophy of the aging human ovary (Laszczynska, et al., 2008). Treatment

had no discernible effect on either ovarian weights or cross-sectional areas. A minor
increase in weight and size in the AMH group at 4 weeks may have been due to mild

transient inflammation previously noted at that time point; however, this was not

statistically significant (P > 0.3).

Figure 3.13 Ovary Weight and Size Decline with Age. Ovaries were dissected from
mice at 4 weeks, 8 weeks, and 10 months after immunization with rmAMH or CFA. The
entire organ was weighed, then fixed and sectioned for measurement. Ovary weight was
normalized to body weight at harvest. (A) Mean weights were stable at 4 and 8 weeks,
then dropped by approximately half by 10 months. (B) Mean cross-sectional area
measurements roughly paralleled weight data. Treatment did not significantly affect
either metric. Error bars represent ±SEM.

In contrast, although ovary weights and cross-sectional areas were similar

between the groups, there was a dramatic difference observed in the numbers of active

follicles present. Again, data were similar between the groups at 4 and 8 weeks, and a

natural decline in follicle numbers was evident in both groups at 10 months. However,
the total numbers of active follicles at 10 months were much greater in mice immunized
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with AMH despite the ovaries having a similar size (Figure 3.14). When quantified by

serial section, mice in the AMH group had an average of 9.25 total follicles per mm22
compared with 3.20 follicles per mm2 in controls, and this difference was significant
(Figure 3.15; P = 0.039).

Figure 3.14. AMH Immunized Mice Have More Active Follicles at Ten Months.
Ovaries were dissected from mice at 4 weeks, 8 weeks, and 10 months after
immunization with rmAMH or CFA. Cross sections were stained with H&E and digitally
imaged. A natural age-related ovarian atrophy was observed at 10 months that affected
both groups approximately equally; however, sections from AMH-immunized mice
revealed greater numbers of active follicles. Representative sections are shown. Sections
from 4 weeks were nearly identical to 8 week sections and are omitted for clarity.
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Time After Immunization

Figure 3.15 AMH Immunized Mice Have Greater Numbers of Total Follicles at Ten
Months. Ovaries were dissected from mice at 4 weeks, 8 weeks, and 10 months after
immunization with rmAMH or CFA. The entire organ was weighed, then fixed and
sectioned and ovarian follicles manually quantified. Total follicle numbers were similar
between the groups at 4 and 8 weeks. At 10 months, a natural decline in follicles was
observed in both groups, but AMH-immunized mice had significantly greater numbers (P
= 0.039). Error bars represent ±SEM.

The difference detected in total follicle numbers between AMH-immunized mice

and CFA controls was further analyzed by follicle subtype. Small, medium, large, and
atretic follicles, as well as corpora lutea (CL), were quantified and compared (Figure

3.16). The AMH group had more follicles in every category, with the greatest divergence
observed in the small and atretic follicle types. While none of these differences
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individually reached statistical significance, they indicate a trend toward follicle
preservation across all subtypes after immunization with AMH.

Follicle Type

Figure 3.16 Follicle Differences by Subtype at 10 Months. Ovaries were dissected
from mice ten months after immunization with rmAMH or CFA. The entire organ was
weighed, then fixed and sectioned and ovarian follicles manually quantified by type:
small; medium; large; total of small, medium, and large (S/M/L); corpora lutea (CL); and
atretic. AMH-immunized mice had greater counts in all categories with the largest
differences in the small and atretic subtypes. Error bars represent ±SEM.
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Because AMH gene expression is proportional to the ovarian reserve (Skiadas, et
al., 2012), the histological findings were further assessed at the molecular level by
measuring AMH gene expression via qRT-PCR. At 8 weeks and 10 months after

immunization, RNA was extracted from the ovaries of mice immunized with rmAMH or

CFA. cDNA was then made from purified RNA, and it was used as a template for qRTPCR using primers specific for mAMH. Gene expression in each sample was normalized
to endogenous P-actin controls, and relative gene expression among samples was

compared. Consistent with the normal age-related decline in ovarian follicles observed
by direct count, AMH gene expression at 10 months dropped to less than one tenth of 8
week levels in both groups (P = 0.001 and P < 0.001; Figure 3.17 A). Also consistent

with histological analysis, AMH-immunized mice exhibited a significant preservation of
the ovarian reserve at 10 months compared to CFA controls, demonstrating 90-fold
greater expression of the AMH gene (P = 0.01; Figure 3.17 B). Despite the differences in

AMH expression between the two groups observed directly in ovarian tissue by qRT-

PCR, no significant difference in serum AMH levels was observed at 10 months by
ELISA (Appendix; Figure S2). Serum FSH levels were similarly assessed by ELISA at 8

weeks and 10 months after immunization. While the data showed the expected natural
age-related increase in FSH in both groups due to the lack of negative feedback from
diminished ovarian reserves (Appendix; Figure S3) and this rise was significant in the
AMH-immunized group (P < 0.05), no significant difference between the groups at either
time point was observed. The seeming disparity between the significantly higher level of

AMH expression in AMH-immunized mice in versus control mice at 10 months

demonstrated by qRT-PCR in ovarian tissues compared with the nearly equal amounts of
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circulating serum AMH shown by ELISA can be explained by the fact that the qRT-PCR
test in this case directly measures the ovarian reserve, and is considerably more sensitive

in this regard than the serum ELISA. There is no evidence to support a possible
compensatory response to the autoimmunity directed at the AMH protein.

Figure 3.17 AMH Immunized Mice Express Greater Levels of the AMH Gene at 10
Months. qRT-PCR analysis of AMH gene expression was performed on cDNA from
ovaries of mice immunized with rmAMH or CFA. (A) Relative AMH gene expression
dropped dramatically and significantly from 8 weeks to 10 months (*P = 0.001; **P <
0.001), but AMH gene expression at 10 months was greater in the AMH-immunized
group. (B) Compared to CFA controls, AMH-immunized mice showed a 90-fold greater
AMH gene expression at 10 months (P = 0.01).
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Immunization with AMH Significantly Lengthens the Estrous Cycle
To further explore the in vivo reproductive physiologic changes mediated by

immunization with AMH, the estrous cycle was analyzed for 52 consecutive days,

capturing an average of ten complete cycles in all mice studied. Four weeks after
immunization with rmAMH or CFA control, vaginal smears were collected at the same

time daily. Samples were methanol fixed, stained with methylene blue, and analyzed by
light microscopy. Estrous stage was determined by the types and numbers of cells
present. The data show striking differences in the cycles of the individual mice between
the groups (Figure 3.18). All of the CFA-immunized mice exhibited a highly regular
pattern of follicular (proestrus + estrus) phases and luteal (metestrus + diestrus) phases.

However, at least half of the AMH-immunized mice demonstrated obvious erratic

patterns with greatly extended follicular and/or luteal phases. The remaining mice in this

group exhibited a subtle lengthening of one or both phases. This elongation of the cycle

resulted in the AMH-immunized group completing significantly fewer cycles over the
duration of the study. This effect is evident in the figure when follicular phase 10 is
highlighted. Only 4/8 mice in the AMH-immunized group reached follicular phase 10,

whereas 8/8 control mice reached follicular phase 10 during the 52 days of observation.
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Figure 3.18 AMH Immunization Disrupts the Estrous Cycle. Vaginal smears taken at
the same time daily for 52 consecutive days were analyzed to determine the stage of
estrous in mice immunized with AMH/CFA or with CFA alone as control. Each
completed cycle consists of the follicular phase (proestrus + estrus; black boxes) and
luteal phase (metestrus + diestrus; white boxes). Follicular phase 10 (if completed) is
highlighted in red. Completed cycles for individual mice are shown stacked with the first
day of the first full cycle aligned at day zero. Mice immunized with AMH/CFA
exhibited significant disruption of the estrous cycle with prominent or subtle elongation
of phases evident. This estrous elongation led to fewer overall cycles completed during
the study period. Only 4/8 mice in the AMH/CFA group reached follicular phase 10,
whereas 8/8 control mice reached follicular phase 10.
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The differences in the number of cycles completed between the means of the two groups
for the duration of the study was significant (Figure 3.19). The CFA controls completed
an average of 11.4 cycles in 52 days, while the AMH/CFA group completed a

significantly fewer average of only 8.9 cycles, a 22% decrease (P = 0.007).

Figure 3.19 AMH Immunization Results in Fewer Estrous Cycles. Vaginal smears
taken at the same time daily for 52 consecutive days were analyzed to determine the stage
of estrous in mice immunized with rmAMH or CFA control. Total numbers of fully
completed estrous cycles within the study period were tallied for each individual mouse.
The means of each group are represented. Mice immunized with rmAMH completed an
average of 2.5 fewer cycles than CFA controls (P = 0.007).

The elongation of the estrous cycles observed in the profiles of individual mice was
quantified and averaged for each group. In CFA control mice, the mean cycle length was

4.5 days. However, mice in the AMH group took about one full day longer for an
average of 5.5 days (Figure 3.20). This 22% increase in length was highly significant (P
< 0.003).
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Figure 3.20 AMH Immunization Lengthens the Estrous Cycle. Estrous staging was
determined by vaginal smear at the same time daily. Total cycle lengths consisting of all
four stages of estrous were averaged for each group. Mice immunized with AMH
displayed a significant increase in cycle length an average of one full day (P < 0.003).
Error bars represent ±SEM.

The differences detected in total cycle length were further subdivided by estrous phase to
determine the individual follicular and luteal contributions (Figure 3.21). The data show

that while the follicular phase was somewhat elongated in the AMH-immunized group,

the majority of the difference observed in total cycle length was due to significant

lengthening of the luteal phase by an average of 0.72 days, a 36% increase (P < 0.02).

93

Figure 3.21 Mean Estrous Phase Length. Estrous staging was determined by vaginal
smear at the same time daily. Mean phase lengths consisting of follicular (proestrus +
estrous) and luteal (metestrus + diestrus) were averaged for each group. Mice immunized
with AMH displayed significantly longer luteal phases by an average of 0.72 days (P <
0.02). Error bars represent ±SEM.
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CHAPTER IV
DISCUSSION

These experiments have shown that immunization of C57BL/6 female mice with
AMH/CFA results in the following: 1) a T cell response characterized by high
frequencies of type-1 and type-17 antigen-specific CD4+ T cells; 2) a significant antigen

specific serum antibody response with dilutions exceeding 1:8,000 even at 10 months

following immunization with AMH/CFA; 3) a transient mild oophoritis characterized by
T cell infiltration of the ovary at 4 weeks but not 8 weeks or 12 weeks after
immunization; 4) a significant extension of fertility characterized by a significant

increase in litter sizes in the fourth mating cycle after immunization, at a time when

fertility normally declines; 5) the extended period of increased fertility is due to a

significant elongation of the estrous cycle confined to the luteal phase; 6) the elongated
estrous cycles in AMH-immunized mice resulted in significantly fewer cycles over the 52

days of experimental observation and thereby, significantly increased follicle numbers
and a preservation of the ovarian reserve. These data are consistent with the view that
AMH-targeted autoimmunity lengthens the estrous cycle and extends fertility long after

the anticipated age-related decline. These observed effects on estrous cycle elongation
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and ovarian reserve preservation are unique for this model of AMH-targeted disruption
and have shed light on the poorly understood role of AMH in controlling fertility and the
ovarian reserve. Thus, these experiments have shown that AMH is a potent immunogen

and that it yields a novel form of EAO which has not been previously described. While
the current model bears some similarities to established models, no immunologic study to
date has demonstrated prolonged fertility during the stage of life commonly associated

with menopause.

Evaluating the Immune Response and Phenotype of AMH Autoimmunity
Immunization with AMH produces a robust antigen-specific CD4+ T cell

response primarily of the type-1/type-17 profile, which is characteristic of autoimmune
disease both in mouse models and in humans (Raphael, et al., 2015). While mild T cell

infiltration was detected in follicles, it was far less pronounced than in the ZP3 and

inhibin-a models (Rhim, et al., 1992; Altuntas, et al., 2006), and it did not result in
observable gross pathology, which stands in contrast to the severe follicular tissue

destruction typical of the NTx model (Taguchi & Nishizuka, 1980). Coupled with the
fact that transfer of T cells alone into naive recipient mice was not sufficient to induce
changes in the estrous cycle (Appendix; Figures S4-S6), these data suggest that the T cell
response is not directly responsible for the phenotype, and that it may only participate

indirectly by providing help to B cells. This hypothesis is further evidenced by the

predominance of high, long-lasting serum titers of AMH-specific antibodies of the IgG1
and IgG2b subtypes, which require the aid of T helper cells to initiate class switching.

These antibodies persist at least 10 months after initial immunization, despite the absence
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of detectable signature cytokines of inflammatory T cells in the ovarian tissue at this

extreme time point. While the type-1 response is traditionally associated with the
development of IgG2a, the C57BL/6 strain used in the study notably cannot produce this
isotype (Martin, et al., 1998). However, it has been shown experimentally that type-17 T

cells alone are capable of driving class switching to all IgG subclasses, including IgG1
and IgG2b (Mitsdoerffer, et al., 2010). Interestingly, these two isotypes also predominate
the humoral response to inhibin-a in SWXJ females in the EAO model (Altuntas, et al.,
2006) and in BALB/c males when inhibin-a is used to vaccinate against testicular cancer

(Aguilar, et al., 2017).
Phenotypically, AMH-immunized mice exhibit unique traits not associated with

existing EAO/POI models. Most strikingly, these mice remain fertile and continue to
produce more litters and larger litters late in life when normal controls begin to exhibit
reproductive senescence. All currently known autoimmune models yield quite the
opposite effect, with fertility diminishing earlier than would be expected for a natural

age-related decline, consistent with human POI. The inhibin-a EAO model shows
biphasic features in that the later decline in fertility is preceded by an earlier phase of

superfertility at 7-9 weeks after immunization. During this same early period, AMH-

immunized mice did not exhibit any statistically-significant increase in pup production.
Concomitant with fertility extension, the AMH EAO model demonstrates enhanced

conservation of follicles late into life, as opposed to the POI-like early depletion seen in
other models. And whereas the inhibin-a EAO model exhibits early-phase

superovulation proceeded by a later stage follicle depletion, superovulation was not
detected in the AMH model at any time point tested. Therefore, the steady and extended
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follicle production and the concomitant extension of fertility with advancing age appear

to be distinct and novel features of the AMH EAO model.

Another unique feature of this model is that the delay in the decline of fertility
and the ovarian reserve in AMH-immunized mice was accompanied by a significant

lengthening of the estrous cycle, with the majority of the extra length occurring in the
luteal (metestrus-diestrus) phase. Estrous disruption is common to many mouse models

of infertility, including the inhibin-a EAO model and the non-ovarian experimental

autoimmune encephalomyelitis (EAE) model, as well as in non-autoimmune ovarian
experimental systems such as the FSH-R (+/-) mouse. However, while both the AMH

and inhibin-a EAO models demonstrated extended luteal phases and longer cycles overall

(Altuntas, et al., 2006), immunization with inhibin-a did so while significantly shortening
the follicular phase (proestrus-metestrus), which was slightly lengthened in the AMH
mouse. In mice immunized with the CNS myelin peptide PLP 139-151 to produce EAE,

a model for human multiple sclerosis (MS), estrous cycles were found to be shortened
overall with the reduction occurring in the follicular phase (Jaini, et al., 2015); this effect
stands in direct contrast to the AMH EAO model, despite the lengthening of the luteal

phase that was common to both models. And finally, while the FSH-R (+/-) mice
initially exhibited lengthened estrous cycles similar to the AMH-immunized mice, they
did so at the expense of early depletion of the ovarian reserve resulting in cessation of

estrous (Danilovich & Sairam, 2002), which was opposite to the effect of ovarian

conservation and extended fertility seen in mice immunized with AMH. Thus, the
specific mode of estrous disruption observed following AMH immunization appears to be

novel.
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Possible Mechanisms of AMH Autoimmunity-Mediated Fertility Extension

It is plausible that the lengthening of the estrous cycle and concurrent decrease in
estrous cycle frequencies could be the primary mechanism by which follicles are

conserved and fertility is extended. Control mice immunized with CFA alone showed a

mean estrous cycle length of 4.5 days and completed a total of 91 complete cycles in the
experimental observation period of 52 days. In contrast, the AMH-immunized mice
showed a mean estrous cycle length of 5.5 days and completed a total of 71 cycles in the

experimental observation of 52 days (Figures 3.19 & 3.20). Thus, the AMH-immunized
mice as a group experienced 20 fewer estrous cycles than the control immunized mice
during the 52 days of observation, for an average of approximately 2.5 fewer cycles per

mouse. This significant decrease in estrous cycle frequency in the AMH-immunized
mice indicates that fewer ovarian follicles were expended, thus conserving the finite
ovarian reserve. This preservation of the ovarian reserve is clearly demonstrated by

histologic follicle counts at 10 months following AMH immunization (Figures
3.14-3.16). The preservation of the ovarian reserve could directly account for the longer

duration of intact fertility. Although the estrous cycle was significantly lengthened, these
elongated cycles did not negatively impact the numbers of litters produced. This is

perhaps a function of the overall rapid nature of the murine estrous cycle itself; because a
female mouse ovulates on average every four days, it is nearly always fertile. The
lengthening of the cycle by one day would not be expected to significantly reduce the
probability of fertilization with the mating male. In addition, since mean litter sizes were
normal, the longer cycle did not appear to affect the number of eggs released during each
ovulation.
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If the elongation of the estrous cycle represents the proximal cause of fertility
extension, the distal cause is the mechanism by which the estrous cycle is lengthened.
One possibility is that the bioactivity of AMH is neutralized by autoantibody that inhibits

the binding of AMH to AMHR2 and/or prevents the enzymatic cleavage of full-length
AMH into its active form. This effect in turn would lower the bioavailable amount of
AMH without necessarily causing a detectable change in serum levels of AMH. A

reduction in active AMH could affect the estrous cycle in multiple ways. Firstly, as the

gatekeeper of the entry and exit of primordial follicles into the developing pool with each
cycle, neutralization of AMH might result in “lifting the brake” on the follicular phase,
allowing more oocytes to participate in each cycle. This effect was observed in the

AMH (-/-) model, in which excessive follicle recruitment early in life caused a premature

depletion of the ovarian reserve (Durlinger, et al., 1999). This finding stands in contrast
to the normal follicle counts early in life and the late-stage conservation of the ovarian
reserve seen in the AMH model. However, the physiologic environment in an

autoimmune model is considerably more nuanced than in a knockout. Autoantibody

neutralization of AMH would not completely eliminate AMH activity, but would most
likely diminish it; the effect may be more akin to the AMH (+/-) mouse, which had an

intermediate phenotype to the AMH (-/-) and wild-type mice in the Durlinger study.
More importantly, AMH knockout mice are completely devoid of any AMH expression
from the moment of conception, and this absence must have significant consequences on

the ovarian reserve during pre-natal development and in the time prior to adulthood. In
the current study, AMH-immunized mice may be considered more of a "functional

conditional knockout/knockdown" that have normal ovarian development and function
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until they are immunized at full maturity, and thus fundamentally differ from AMH (-/-)
mice. Alternatively, in the AMH EAO model it is possible that a reduction of AMH
activity may in essence relieve apoptotic pressure—instead of simply lifting the brake to

allow greater numbers of oocytes to enter and exit the developing pool, it may cause
fewer oocytes per cycle to undergo apoptosis. In this scenario, reduction of AMH
activity would allow normal ovulation rates and typical litter sizes while preserving the
absolute numbers of primordial follicles in the reserve, thus extending the fertile lifespan

of the mouse. This mechanism would best fit the phenotype of AMH autoimmunity in
the current study; moreover, a similar phenotype of extended fertility due to conservation

of the ovarian reserve was described in a mouse model in which the pro-apoptotic gene
Bax was knocked out (Perez, et al., 1999).

While the effect of a reduction of bioavailable AMH on follicular development
may help explain the extended conservation of the ovarian reserve, it does not directly

account for the lengthening of the estrous cycle in AMH-immunized mice. The estrous
cycles of Bax (-/-) mice were not analyzed, and AMH (-/-) mice did not exhibit

significant differences in the estrous cycles from their wild-type counterparts until they
became acyclic from exhaustion of the ovarian reserve. The elongation of the estrous

cycle evident in the AMH EAO model clearly cannot be explained by modulation of
apoptosis alone. However, a reduction of AMH activity could also exert influence on the

hormonal control of the estrous cycle. It has been reported that AMH inhibits aromatase

activity, thereby opposing production of estrogen from precursor androgens (Pellatt, et
al., 2011; Sacchi, et al., 2016). A decrease in AMH activity would therefore lead to

greater estrogen levels, which in turn would increase negative feedback on the pituitary
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gland—which ultimately drives the cycle by secreting FSH and LH. Therefore, it is

plausible that increased negative feedback on the pituitary could be the means by which
AMH autoimmunity slows the cycling process and thereby lengthens the estrous cycle.
In the current study, the mean FSH levels in the serum of mice immunized with AMH

were slightly lower than CFA controls at 8 weeks, although this effect did not reach
significance (Appendix; Figure S3). Further investigation with larger numbers of mice

and time points matched to specific stages of estrous may be necessary. In addition,

direct measurement of estradiol at these time points may shed further light on this

process.
Although the ultimate mechanism by which AMH autoimmunity exerts its effect

remains speculative, multiple lines of evidence suggest that the physiologic effect is
mediated by autoantibody neutralization of AMH. As previously mentioned, persistently

high antibody titers were observed as late as ten months after immunization, and T cell

infiltration of ovarian tissues was mild and transient. Additionally, in vitro evidence

revealed negligible CD8+ activation, which suggests that cytotoxic T cells are not a
relevant effector cell in the AMH immune response. Furthermore, no gross pathology or
tissue damage was evident in the ovaries at any time point. Thus, it is likely that the
mechanism of action is non-destructive, and therefore does not involve antibody

dependent cellular cytotoxicity (ADCC) or complement fixation. The lack of complement
involvement is further evidenced by negative staining for C4d, a definitive marker for
antibody-mediated complement fixation (Murata & Baldwin III, 2009). Lastly, antibody
neutralization is the mechanism of action in the inhibin-a EAO model, which also
exhibits high titers of the isotypes IgG1 and IgG2b. Although there is much evidence to
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suggest that antibody neutralization of AMH is the ultimate cause of fertility extension, it

was not demonstrated directly in the current study and it remains an area of focus for
future research. Although many questions remain to be addressed, taken together, the
findings in the current study suggest a possible mechanism by which AMH

autoantibodies may exert their influence to lengthen the estrous cycle, preserve ovarian
follicles, and ultimately extend fertility. A working model of these processes is proposed

in Figure 4.1.
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Figure 4.1 Proposed Mechanism for AMH Autoantibody-Mediated Fertility
Extension. High titers of circulating AMH autoantibodies lower the bioactive amount of
AMH by direct neutralization of its activity and/or preventing cleavage to the active form
(1). With less bioactive AMH in the ovarian microenvironment, apoptosis is reduced and
fewer follicles undergo atresia (2). Simultaneously, the natural inhibition of aromatase
by AMH is diminished, allowing greater production of estrogen by the ovarian follicles
(3). An elevated level of estrogen exerts negative feedback on FSH and LH production
by the pituitary (4), which in turn causes a slowing of the ovarian cycle rate (5). Taken
together, the preservation of the ovarian reserve by reduced atresia and fewer cycles over
time may account for the extension of fertility observed in AMH-immunized mice.
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Insights Gained into the Natural Functions of AMH
The knowledge acquired in the AMH autoimmunity model may be useful in

elucidating the true physiologic role of AMH. As previously noted, although an AMH
knockout mouse has long existed, these mice lack AMH production from the moment of

their conception, and therefore do not accurately represent women who are born fertile
but develop POI later in life. Immunization with AMH offers a convenient method of

creating a “functional conditional knockout/knockdown" system in which AMH can be
targeted at any stage of life after normal development has occurred. And surprisingly,

despite the abundance of current in vivo and in vitro models, and after nearly 40 years of

research on AMH in the ovary, its precise role in females remains a topic of debate. In
fact, even the most basic molecular function of AMH—whether it inhibits or promotes

cell growth—remains controversial. Although the majority of scientific literature
describes AMH as a pro-apoptotic, there is also considerable published evidence to

suggest exactly the opposite (Pankhurst, 2017). The accumulation of contradictory
evidence regarding the basic function of AMH, as well as its role in the mature female,

has shaped a murky understanding of the hormone and its physiologic significance.
However, a unified concept of AMH as a subtle yet essential regulator of the ovarian

reserve has begun to emerge.

The earliest known function of AMH—to cause regression of the Mullerian ducts
in the male fetus—clearly demonstrates its ability to promote apoptosis (Roberts, et al.,
1999; Xavier & Allard, 2003). Moreover, it has been shown that the canonical pathway
of AMH/AMHR2 signaling in adult tissues leads to cell cycle arrest and apoptosis

(Namkung, et al., 2012; Zhang, et al., 2018) as well as to the induction of pro-apoptotic
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genes such as Bax (Mazumder, et al., 2017). As it belongs to the TGFP superfamily, it is
not surprising that AMH would share this capacity with the namesake member.
However, the actions of TGFP itself are diverse, ranging from apoptosis to cell growth,

cell differentiation, and immunomodulation (Clark & Coker, 1998; Shi & Massague,
2003). Therefore, it follows that AMH may also have pleiotropic effects, some of which
may not yet be defined.

The outcomes of in vitro studies designed to test the effects of AMH have varied
enormously. AMH has been shown to inhibit the growth of AMHR2-expressing human
GCTs by activating apoptosis (Anttonen, et al., 2011), Furthermore, AMH treatment can
inhibit chemotherapy-resistant ovarian cancer progenitor cells (Meirelles, et al., 2012) as

well as cervical cancer (Barbie, et al., 2003). In addition to its efficacy against

gynecologic tumors, AMH treatment is effective against cancers originating from
AMHR2-expressing neural-derived tissues, such as human ocular melanoma (Parry, et

al., 1992). However, in stark contrast to these pro-apoptotic effects, Schmidt and
colleagues demonstrated that AMH added to human ovarian explants in culture

stimulated growth of primordial follicles (Schmidt, et al., 2005). From these diverse
studies, it is not clear if the functions of AMH vary depending on context, or if
differences in methodologies may account for the observed contrasting effects.

Similarly, in vivo murine models have produced conflicting results. The AMH

null mouse model surprised investigators in that AMH (-/-) females are initially fertile;
the early implication was that AMH is not required for fertility and therefore rather

unimportant in the ovarian cycle. However, as these mice eventually show premature

depletion of their ovarian reserve, AMH became appreciated as an essential regulator of
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the oocyte supply (Durlinger, et al., 1999). It was subsequently demonstrated that this
effect was mediated through opposing FSH recruitment of preantral follicles, allowing

AMH to influence management of the reserve (Durlinger, et al., 2001). More recently, a

contrasting animal model has been developed in which mice overexpress AMH shortly
after birth. Unlike their counterpart knockout mice, Thy1.2-AMHTg mice have severe
fertility impairment from the outset, birthing infrequent and small litters compared to

wild-type mice (Pankhurst, et al., 2018). Surprisingly, despite having the opposite
genotype to AMH null mice, the phenotype of the Thy1.2-AMHTg AMH-overexpressing

mice ultimately parallels the phenotype of the knockouts, with the ovarian reserve being

depleted as early as five months of age. Similar to in vitro data, these geneticallyengineered mouse models initially suggest contradictory effects of the role of AMH in
maintaining the ovarian reserve. Whether AMH is overexpressed, or not expressed at all,

the eventual outcome is the same—premature exhaustion of the oocyte supply. This

result stands in contrast to the AMH autoimmunity model described here, in which the
ovarian supply is conserved. However, the fact that a similar phenotype of extended

fertility was observed in the mouse model in which the pro-apoptotic Bax gene was
knocked out (Perez, et al., 1999) provides indirect support for an apoptotic role of AMH.

Although it is difficult to reconcile the disparate results of all in vitro and in vivo
studies, perhaps the overall lesson is that function of AMH is nuanced, and may differ

based on context, i.e., the type of target cell, the timing and location, and other factors in
the local microenvironment. AMH may in fact have different physiologic effects

depending on the stage of development of the target follicle. In a recent study in which
normal C57BL/6J mice were injected with exogenous bioactive AMH daily for 4 weeks,
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the authors concluded that AMH both inhibited follicle development and also reduced the

rate of atresia by an unknown mechanism (Hayes, et al., 2016). Curiously, these mice
demonstrated extended conservation of the ovarian reserve, which is unexpectedly
inconsistent with the phenotype of the AMH-overexpressing Thy1.2-AMHTg mouse and

more congruent with the results of the current study in which AMH is targeted
immunologically. Nevertheless, it is conceivable that AMH may be working at both ends

of the folliculogenesis process, limiting the amount of the total reserve recruited into the

developing pool with each cycle, as well as influencing the rate of atresia—either by
promoting it, inhibiting it, or both (Visser, et al., 2007; Seifer & Merhi, 2014). The
delicate balance of the entry and exit of follicles into this cyclic pool known as the

"dynamic reserve" is critical for the proper maintenance of fertility, and AMH clearly
plays a key role (Monniaux, et al., 2014; Pankhurst, 2017). Therefore, any change in the

bioavailable amount of AMH could have complex effects on follicle regulation.

Ultimately, some of the conflicting data on the role of AMH may be due in part to
limitations inherent in the study techniques used. Tissue culture is by nature a

reductionist approach that is devoid of the intricate network of endocrine glands and
hormones that are normally in play. Knockouts and transgenic animals create an artificial
system in which the expression of the target protein is absent or not regulated, and the

normal developmental patterns of expression are nonexistent. Taken together, there are
unavoidable artifacts generated by all of the existing models. This dilemma necessitates
the development of an in vivo system with a normal developmental expression pattern of
AMH which can be disrupted at will by the investigator. Immunization with AMH may

provide exactly these tools for the study of the hormone and its properties.
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Insights on Menopause and Aging
Although the AMH autoimmunity model bears many similarities to other

established models of human infertility, it does not share all of the features with any of

them; nor does it specifically mimic any known human disorder (Table 4.1). Thus, the
AMH EAO model may serve as a novel approach for studying the role of AMH in

fertility, but moreover, it may represent a potentially unrecognized human condition.
Regarding the unexpected superfertility observed in the inhibin-a EAO model, Altuntas
and colleagues state that " ... Human POF may possibly be biphasic with an early

clinically silent and undetected period of enhanced fertility followed by a detected later
period of infertility ... the early period of enhanced fertility would likely be detected only
if the woman became pregnant and had multiple births" (Altuntas, et al., 2006). In a
similar manner, AMH autoimmunity may remain clinically silent, as a young woman
may have slightly longer than average menstrual cycles and normal fertility; and although
her fertility may be preserved much later in life than average, this fact may not be evident

if she is no longer attempting to conceive. In the United States, the vast majority of

babies are born to women under 40. In 2017, only 3.2% of all live births were attributed
to mothers aged 40 or above; births to mothers over 50 were extremely rare, representing

only 0.02% of total live births (Centers for Disease Control and Prevention, 2018).
Although it is difficult to estimate the relative contributions of family planning and
fertility in this age group, the timing coincides with the age of menopause and
perimenopause, and therefore reproductive senescence must have a major impact.
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Model/Disease

T Cell
Infiltrate

Antibody
Titers

Neonatal thymectomy

severe

high

Ovarian homogenate
ZP3 peptide

moderate
severe

high
high

Inhibin-a peptide

moderate

high

rAMH

mild

high

Estrous/Menstrual
Cycle
Immunologic Ovarian
Normal

Irregular

Lengthened cycle;
shortened follicular,
lengthened luteal
Lengthened cycle;
lengthened luteal

PLP peptide (EAE)

-

-

Bax (-/-)
AMH (-/-)
FSH-R (+/-)
LHCGR Mutation
Thy1.2-AMHTg
rAMH-C treatment

-

-

POI

Present*

Present*

PCOS

Possible*

Present*

Immunologic Non-Ovarian
Shortened cycle;
lengthened follicular,
shortened luteal

Ovarian
Reserve/Fertility

Reference

-

(Taguchi, et al., 1980; Murali,
et al., 2020)
(Jankovic, et al., 1973)
(Rhim, et al., 1992; Fu, et al.,
2007)
(Altuntas, et al., 2006)

Fertility impaired

Biphasic: early
superfertility, then
early depletion
Conserved

-

(Johnson, 2020)

(Jaini, et al., 2015)

Non-Immunologic Ovarian
Normal
Irregular/lengthened
Irregular/lengthened
Normal
Irregular

Conserved
Early depletion
Early depletion
Early depletion
Early depletion
Conserved

(Perez, et al., 1999)
(Durlinger, et al., 1999)
(Danilovich & Sairam, 2002)
(Hai, et al., 2015)
(Pankhurst, et al., 2018)
(Hayes, et al., 2016)

Clinical Ovarian Disease
Absent

Early depletion

(Silva, et al., 2014; Kovanci &
Schutt, 2015)
(Nasri, et al., 2018; Mobeen, et
al., 2016; Sirmans & Pate,
2013)

Irregular, prolonged,
or absent

Fertility impaired

Table 4.1. Comparison of Phenotypes in Animal Models of Infertility and Human Disease. Major findings and key references
are noted. Dashes indicate data that are not applicable or unreported. *In clinical cases with an underlying autoimmune cause.
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Nevertheless, the CDC reports 840 births in 2017 to women aged from 50 all the way up

to 65 (Centers for Disease Control and Prevention, 2018). It is an intriguing proposition
that these remarkable birth events late in life may be attributable to a spontaneous

extension in fertility, and that while beguilingly rare, at least some of these births could
be the result of a silent undetected AMH autoimmunity.
One indisputable fact is that the level of AMH found in the serum of healthy
women is proportional to the ovarian reserve, and AMH is widely accepted as a

predictive marker of fertility as well age at menopause (Tehrani, et al., 2011; Kruszynska
& Slowinska-Srzednicka, 2017). However, its precise role in the natural process of

reproductive senescence is unknown. It may be merely an indicator of follicular activity,

or it may actually play an active part in determining the timing of menopause. To
understand how and why AMH is significant in this regard, it is necessary to understand

the role of menopause itself; however, even the question of why menopause exists is

fraught with debate. While reproductive senescence is common in the animal kingdom,
menopause, or the complete cessation of fertility, is not—along with humans, it is shared
by a handful of other animals, including rodents, dogs, non-human primates, elephants,

and whales (Packer, et al., 1998). It is intriguing that humans and many of these animals
share the trait of longevity. It has been suggested that menopause exists simply because

humans now live considerably longer than our cave-dwelling ancestors, and that women

simply outlast their natural fertile lifespan (Blurton Jones, et al., 2002). However, there
are several prevailing theories (reviewed in Wu, et al., 2005) rooted in Darwinian natural
selection. The "Good Mother Hypothesis" purports that menopause necessitates a focus

on raising present children rather than having additional children, and thus exerts a
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"quality over quantity" paradigm on motherhood (Sherman, 1998). The "Grandmother

Hypothesis" applies the same logic to the postmenopausal stage, in which the

grandmother can invest effort into helping raise her grandchildren, thus further ensuring
the survival of her inherited genes (Kim, et al., 2019). In contrast, the "Disposable Soma

Theory" states that organisms, having limited cellular resources, must trade off
maintenance of somatic systems with reproductive systems. The soma must be
maintained to the degree in which the animal is likely to survive in the wild, and the

reproductive lifespan is independently maintained to match this extent. Inevitably, if the
animal lives longer than anticipated, the investment in reproduction is expended and its
consequences in soma neglect is witnessed by the effects of bodily aging (Kirkwood,

2002). Thus, this theory lends a Darwinian underpinning to the notion that menopause is
the inevitable product of longevity.

While the “Disposable Soma Theory” may imply that reproductive lifespan is
actively matched to the anticipated lifespan of the organism, the converse may be true.

There is accumulating evidence to support a strong positive correlation between age at

menopause and longevity. Using an epigenetic biomarker of age, Levine and colleagues

found an association between early menopause and accelerated aging (Levine, et al.,

2016). This finding held true whether menopause was natural or surgically induced by
oophorectomy. Interestingly, women who received menopause hormonal therapy
exhibited a lower epigenetic age. Taken together, the authors conclude from these results
that menopause is likely the cause of the observed accelerated aging. If true, it follows
that delaying the onset of menopause would extend natural lifespan. The possibility that
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the fertility extension imparted by AMH immunization may increase longevity is enticing

and warrants further study.

As additional evidence for the link between AMH and longevity, it has been
shown that age at natural menopause (ANM) is governed in part by variants in the AMH
and AMHR2 genes. A number of single nucleotide polymorphisms (SNPs) have been
identified that modify the ANM (Braem, et al., 2012). Intriguingly, in an unrelated study

of the proteomes of dozens of mammalian species to find longevity-selected positions,
the cytoplasmic kinase domain of AMHR2 stood out as the protein domain most strongly

associated with longevity (Semeiks & Grishin, 2012). These studies provide molecular
insights into how AMH may provide a link between reproductive lifespan and the

lifespan of the organism, and suggest that the AMH/AMHR2 signaling may be ideal for
targeting clinical therapies for either or both matters.

Novel Clinical Applications for AMH
In a clinical setting, AMH and its receptor could be exploited in a number of

novel ways for human benefit. For example, the measurement of AMH levels in serum

has already proven its diagnostic value in cases of infertility; however, evaluating AMH
autoantibody levels in serum to assess infertility could prove to be useful in identifying
the root cause—and a possible treatment path—in idiopathic cases. In addition to its
diagnostic value, AMH could be targeted immunologically in order to actively intervene

in human diseases and conditions. As AMH immunization has been shown in the current
study to delay reproductive senescence in a mouse model, this discovery suggests that the

same method could potentially extend fertility and delay menopause in humans. This
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approach could be of great benefit for women who choose to have children later in life

for career or other personal reasons, as these women often run the risk of fertility

problems by postponing childbearing. Additionally, by delaying the onset of menopause,
these women would avoid the serious accompanying health risks such as osteoporosis

and cardiovascular disease.
The concept of harnessing autoimmunity to modulate fertility has been proposed

in the past; for example, Millar and colleagues suggested that immunization or women
with ZP3 peptide could be employed to provide long-term contraception, and that passive
transfer of ZP3 antibody could provide a reversible form of contraception (Millar, et al.,

1989). The contrast between these two modes highlights one of the greatest potential

pitfalls of active immunization—unlike conventional drugs, a vaccination cannot be

withdrawn. Therefore, if the patient changes her mind, or if an adverse effect occurs, the
path ahead may be difficult. Given the in vitro and mechanistic data presented in the

current study, passive transfer of antibody may be effective for fertility extension.
However, it may be challenging to deliver and maintain a clinically effective amount of

antibody over a span lasting potentially decades. Additionally, ethical consideration must
be given to the circumstances of a child born to a mother over 50, 60, or even 70.

Children of mothers of extremely advanced age may have an unfair disadvantage or

experience poor quality of life. Of greater concern, the health of the child may also be at
risk, since health risks in pregnancies increase with the age of the mother (Coco, et al.,

2014).
In addition to the general risks associated with pregnancies in older mothers, there

is a chance that AMH autoantibody of the IgG isotype may cross the placenta. In the
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case of a male fetus, neutralizing antibody could reduce the amount of bioavailable

AMH, causing PMDS. This scenario was demonstrated experimentally in rabbits (Tran,
et al., 1986) and raises the question of whether this condition occurs naturally, and
whether maternal AMH antibodies account for at least some of the spontaneous cases of
PMDS in humans. An analogous model in mice would likely not be feasible, as very
little maternal-fetal IgG transfer in this species occurs, and only very late in gestation;

however, significant amounts of IgG is transferred postnatally through lactation (Pentsuk
& van der Laan, 2009). All pups in the current study were euthanized shortly after birth

and no internal examinations of urogenital structures were performed; however, this will

most certainly be an avenue for future study. Furthermore, the long-term effect on the
fertility and ovarian reserve in female pups born and nursed by AMH-immunized

mothers makes an intriguing area of further investigation.
Finally, the fact that AMH is no longer expressed in women after menopause

positions the protein as an appealing target antigen for developing a preventive or

therapeutic ovarian cancer vaccine. Active immunization to what has been termed
"retired self-proteins" (Tuohy, 2014) would be expected to produce a benign

immunologic memory in a woman no longer producing AMH; however, an emerging
ovarian tumor aberrantly producing AMH would be immediately recognized by immune
surveillance and destroyed. The active immunization approach to cancer treatment and

prevention has the intrinsic benefit that it is long-lasting and self-sustaining, unlike

passively transferred immunotherapeutics. For example, the humanized monoclonal
antibody Avastin® (bevacizumab) effectively targets vascular endothelial growth factor A
(VEGF-A) to inhibit the development of blood vessels that would nourish emerging and
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growing tumors, and the drug has been approved by the FDA to treat many types of
cancers including colorectal, breast, and more recently for stage III/IV ovarian cancer.
However, due to the limited half-life of the antibody, the patient must receive i.v.
infusions of the drug every 3 weeks for as many as 22 cycles. A treatment regimen may

cost upwards of $100,000 per year, and when used in combination with standard

chemotherapeutic agents against well-established tumors, may only extend the life
expectancy of a patient by five to six months (Fleck, 2006; Rossi, et al., 2017). The
paradigm of targeting organ-specific retired self-proteins with active immunization

overcomes the need for repeated and costly administration of a passive agent, and the
approach has been successful in preventing or treating tumors in murine models of breast

cancer (Jaini, et al., 2010) and ovarian cancer (Sakalar, et al., 2015; Mazumder, et al.,

2017). In the ovarian cancer vaccine model, it has been demonstrated that vaccination of
mice with extracellular domain of AMHR2 (AMHR2-ED) is highly effective in

inhibiting the growth of autochthonous and transplantable epithelial ovarian carcinomas

(EOCs). While the full-length protein is not completely "retired" with age akin to its
ligand, the extracellular domain of AMHR2 in humans is no longer expressed at

autoimmunogenic levels in any human tissues after menopause (Mazumder, et al., 2017).
While the physiologic purpose of this age-related variant of the receptor is unclear, it
creates an opportunity to target a domain that is no longer expressed in healthy tissues,
but is expressed at high levels in >90% of human EOC. AMH may be similarly

employed in a vaccine aimed at primary immunoprevention and treatment of ovarian
cancer. This strategy should be reasonably safe for any postmenopausal woman, but it

may not be nearly as effective as the AMHR2 approach. Ovarian tumors that secrete
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AMH are almost exclusively limited to those arising from granulosa cell tumors (GCTs),

and these tumors represent only 3% - 5% of ovarian neoplasms (Chang, et al., 2009).

Additionally, since AMH itself has been shown to have intrinsic anti-cancer properties
(Kim, et al., 2014), one must consider that immunologic targeting of AMH may have the
unintended effect of alleviating any natural apoptotic pressure that AMH naturally exerts

on the tumor. However, in the current study, no ovarian neoplasms were observed during

necropsy at any time point, including those as long as ten months from immunization.
This finding implies that even a prolonged history of anti-AMH immunity at least does
not promote tumor development, and should be explored as a means of cancer
prevention. Finally, while no obvious abnormalities were discovered in brain tissues or

behavior of mice in the study, it is important to note that AMH expression in the brain is
negligible in mice but substantial in humans (Uhlen, et al., 2015). While it remains

unclear if AMH expression in the human brain is "retired" after menopause as it is in the
ovaries, the possibility of off-target CNS effects remains a caveat for any human
application of AMH autoimmunity. Nevertheless, the promise of a potential novel
ovarian cancer vaccine remains appealing, and determining whether AMH vaccination is

ultimately effective in preventing or treating GCTs in a mouse model will be addressed in
future investigations.
In summary, the current study has for the first time generated and characterized

the immune response to anti-Mullerian hormone in a murine model. Additionally, a
novel phenotype of extended fertility has been identified, and this discovery may be

important not only in unraveling the true nature and biologic functions of AMH, but also

in better understanding and treating impairments of human fertility. In the seminal paper
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describing the first successful model of EAO, the hopeful and insightful conclusion
reached by the authors states: "Finally, these results suggest that autoimmune ovariopathy

should be given consideration when treating problems related to fertility and sterility"
(Jankovic, et al., 1973). These investigators recognized the significance of their

findings—that autoimmune infertility was likely a dreadful and widespread disease
hiding in plain sight. Nearly half a century later, this hypothesis has been supported by

overwhelming experimental and clinical evidence. The evidence presented herein will

hopefully add to the collective wealth of knowledge of human infertility and the means to
address it.
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SUPPLEMENTARY DATA

Figure S1. Complement Activity is Absent as Evidenced by Negative C4d Staining
in Ovarian Tissues. Sections of ovaries from mice immunized with rmAMH or CFA
were immunostained with C4d antibody and analyzed by light microscopy. C4d staining
was absent at 4 weeks after immunization for both (A) AMH and (B) CFA mice as well
as at 8 weeks after immunization for both (C) AMH and (D) CFA mice. Scale bar
represents 50 |im.
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Figure S2. Serum AMH Levels at 10 Months. Ten months after immunization with
rmAMH or CFA, mice were euthanized and serum collected via cardiac puncture. Sera
were diluted 1:3 with PBS and analyzed via competitive ELISA for mouse AMH. Means
for each group are plotted. No significant difference was observed between the groups.
Error bars represent ±SEM.
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* P< 0.05

8 Weeks

10 Months

Figure S3. Serum FSH Levels at 8 Weeks and 10 Months. At eight weeks and ten
months after immunization with rmAMH or CFA, mice were euthanized and serum
collected via cardiac puncture. Sera were analyzed via sandwich ELISA for mouse FSH.
Means for each group are plotted. The increase in FSH from 8 weeks to ten months was
significant (P < 0.05). However, no significant differences were observed between the
groups at either time point. Error bars represent ±SEM.
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Component
Figure S4. Total Estrous Cycle Lengths in Passive Transfer to Naive Hosts. Four
weeks after immunization with rmAMH or OVA control, splenocytes and serum were
harvested from mice. Purified CD4+ T cell and B220+ B cell populations were produced
from whole splenocytes by MACS positive selection. Naive mice received a single i.p.
injection of 2 x 107 activated T cells or B cells, or four i.v. injections of 200 |1L of serum
every third day. After one week, estrous cycles were evaluated as previously described.
The mean total cycle lengths are plotted for each group. No significant differences were
observed. Error bars represent ±SEM.
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Follicular Phase

Component
Figure S5. Follicular Phase Lengths in Passive Transfer to Naive Hosts. Four weeks
after immunization with rmAMH or OVA control, splenocytes and serum were harvested
from mice. Purified CD4+ T cell and B220+ B cell populations were produced from
whole splenocytes by MACS positive selection. Naive mice received a single i.p.
injection of 2 x 107 activated T cells or B cells, or four i.v. injections of 200 |1L of serum
every third day. After one week, estrous cycles were evaluated as previously described.
The mean follicular phase lengths are plotted for each group. No significant differences
were observed. Error bars represent ±SEM.
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Luteal Phase

Component
Figure S6. Luteal Phase Lengths in Passive Transfer to Naive Hosts. Four weeks
after immunization with rmAMH or OVA control, splenocytes and serum were harvested
from mice. Purified CD4+ T cell and B220+ B cell populations were produced from
whole splenocytes by MACS positive selection. Naive mice received a single i.p.
injection of 2 x 107 activated T cells or B cells, or four i.v. injections of 200 |1L of serum
every third day. After one week, estrous cycles were evaluated as previously described.
The mean luteal phase lengths are plotted for each group. No significant differences
were observed. Error bars represent ±SEM.
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